Document:

Restated and Amended License Agreement between Nektar Therapeutics

 EXHIBIT 10.27 
 [ * ] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
 RESTATED AND AMENDED LICENSE AGREEMENT 
 THIS RESTATED AND AMENDED LICENSE AGREEMENT (the “Agreement”) is made and entered into as of August 7,
2006 (the “Effective Date”) by and BETWEEN NEKTAR THERAPEUTICS UK LIMITED, a limited company organized under the laws of England and Wales
(“NEKTAR UK”), and MAP PHARMACEUTICALS, INC., a Delaware corporation (“MAP”) and amends, restates, supersedes and replaces that certain License and
Supply Agreement (“Prior Agreement”) made and entered into as of June 22, 2004 by and between NEKTAR UK and MAP. NEKTAR UK and MAP are sometimes referred to herein individually as a “Party” and collectively as
the “Parties”. 
 RECITALS 
 WHEREAS, NEKTAR UK has been engaged in the research and development of engineered particles to enhance the therapeutic performance of compounds (to be administered by pulmonary or
aerosol delivery) using its proprietary supercritical fluid particle formation technology, including but not limited to solution enhancement dispersion of supercritical fluid particles (“SEDS Technology”); 
 WHEREAS, MAP is engaged in the research and development of proprietary delivery systems, e.g., devices and
formulations suitable for those devices for administering drugs by inhalation, including the pharmaceutical compound, dihydroergotamine [ * ] and its isomorphs and isomers; 
 WHEREAS, MAP and NEKTAR UK (or NEKTAR UK’S Affiliate, Nektar Therapeutics) entered into a Mutual Non-Disclosure
Agreement effective March 9, 2004 (the “Nondisclosure Agreement”) relating to the exchange of confidential and proprietary information regarding engineered particles of pharmaceutical compounds for administration by inhalation;
and 
 WHEREAS, under the Prior Agreement, MAP obtained and NEKTAR UK granted to MAP a license under
certain of NEKTAR UK’s proprietary technology to develop, manufacture, market and sell a Product that combines a Formulation, based upon a Particulate Formation of Compound, together with an inhalation device on the terms and conditions
provided in the Prior Agreement 
 WHEREAS, under the Prior Agreement, NEKTAR UK was to supply to MAP,
clinical quantities of such Particulate Formation of Compound that met GMP requirements and the Parties were to negotiate and enter into a commercial supply agreement for such Particulate Formation of Compound; and 
 WHEREAS, the Parties desire to amend and provide for termination of obligations under the Prior Agreement for supply
by NEKTAR UK and purchase by MAP of such Particulate Formation of Compound, to adjust payments to be made by MAP to NEKTAR UK, to state NEKTAR UK’s obligation to provide documents pertaining to such Particulate Formation of Compound, and to
make NEKTAR UK’s other technical and regulatory support obligations subject to mutual agreement, and provide for NEKTAR UK to transfer to MAP certain manufacturing equipment useful for manufacture of such particulate formulation. 

 NOW, THEREFORE, in consideration of the foregoing
recitals and the covenants and promises contained in this Agreement, the Parties agree as follows: 
 AGREEMENT 
 1.      DEFINITIONS. As used herein, the following terms shall have the following meanings:

 1.1      “Affiliate” means a corporation, partnership, trust or other entity that
directly, or indirectly through one or more intermediates, controls, is controlled by or is under common control with a Party to this Agreement. For such purposes, “control,” “controlled by” and “under common control
with” shall mean the possession of the power to direct or cause the direction of the management and policies of an entity, whether through the ownership of voting stock or partnership interest, by contract or otherwise. In the case of a
corporation, the direct or indirect ownership of more than fifty percent (50%) of its outstanding voting shares or the ability otherwise to elect a majority of the board of directors or other managing authority of the entity shall in any event
be deemed to confer control, it being understood that the direct or indirect ownership of a lesser percentage of such shares shall not necessarily preclude the existence of control. 
 1.2      “NEKTAR UK Core Technology” means products, processes, methods, technologies and other
inventions (whether or not patentable) Controlled by NEKTAR UK and related to particulate formations of pharmaceutical compounds for delivery by inhalation using NEKTAR UK proprietary technologies, including but not limited to SEDS Technology and
the use of SEDS Technology to prepare, purify, assay, formulate, micronize or process pharmaceutical compounds (including without limitation to apply the SEDS Technology to the Compound to prepare the Particulate Formation of Compound). NEKTAR UK
Core Technology excludes (a) technologies solely relating to: the Compound or a Device, and (2) products, processes, methods, technologies and other inventions in the public domain that are owned or made by Third Parties (other than on
behalf of NEKTAR UK or its Affiliates) and not Controlled by NEKTAR UK or its Affiliates. 
 1.3      “NEKTAR UK Know-How” means all Information that is (a) Controlled by NEKTAR UK at any time during the term of this Agreement and (b) useful or necessary in the Field.
NEKTAR UK Know-How does not include NEKTAR UK Patent Rights. 
 1.4      “NEKTAR UK Patent
Rights” means the rights granted by any governmental authority under any Patents and Patent Applications Controlled by Nektar UK that, assuming such Patent Applications were issued Patents, but for the grant of the license in
Section 2.1, would be infringed by the manufacture, use, import, export, offer for sale or sale of a Particulate Formation of Compound, including without limitation a Particulate Formation of Compound or Product by or on behalf of MAP (other
than by NEKTAR UK), including without limitation those Patents and Patent Applications listed on Exhibit 1.4. NEKTAR UK Patent Rights do not include NEKTAR UK Know-How. NEKTAR UK represents that it has used good faith efforts to include on Exhibit
1.4 all NEKTAR UK Patent Rights existing as of the Effective Date. Once per calendar year or as reasonably requested by MAP, the Parties will update Exhibit 

  

 2 
 [ *
] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
1.4 to include all NEKTAR UK Patent Rights. If, as of the Effective Date or during the term immediately after any update pursuant to the previous sentence,
Exhibit 1.4 does not include any NEKTAR UK Patent Rights, the Parties will in good faith update or correct Exhibit 1.4 as applicable, and this shall be each Party’s sole remedy for any omissions from Exhibit 1.4. 
 1.5      “Commercial Launch” means on a country-by-country basis, the first sale of a Product to a
Third Party following Regulatory Approval of the Product in such country. 
 1.6      “Compound” means dihydroergotamine [ * ] or isomorphs or isomers thereof. 
 1.7      “Compound-Limited Claims” means all claims of those NEKTAR UK Patent Rights listed in Exhibit 1.4 or that are not listed in Exhibit 1.4 that claim
Compound, formulations of Compound, compositions of matter, methods of manufacture or methods of using Compound or formulations of Compound, including without limitation the Particulate Formation of Compound and Formulation, whether or not such
claims claim any compositions of matter, methods of manufacture of methods of using other compounds or formulations of such other compounds. 
 1.8      “Compound-Inclusive Claims” means all claims of NEKTAR UK Patent Rights that are not Compound-Limited Claims. 
 1.9      “Confidential Information” has the meaning set forth in Section 11.1. 
 1.10      “Compulsory License” means a compulsory license under the NEKTAR UK Patent Rights
obtained by a Third Party through the order, decree, or grant of a competent governmental authority, authorizing such Third Party to manufacture, use, import, export, offer for sale or sell Product in a particular country. 
 1.11      “Control” means having ownership of or a license to an intellectual property or other
right with the ability to grant a license or sublicense as provided for herein without violating the terms of any agreement or other arrangement with any Third Party. 
 1.12      “Device” means any device designated by MAP for use for inhalation by means of nasal delivery or pulmonary delivery of the Formulation that is suitable
for use in clinical trials for the Product and commercialization of the Product, including devices for which MAP owns an exclusive license in the Field for such purpose. Unless otherwise noted, the use of the term “Device” in this
Agreement is not intended to indicate thereby the definition of “device” in the Federal Food, Drug and Cosmetic Act, as amended. Notwithstanding any other provision of this Agreement, NEKTAR UK does not grant to MAP any license or other
right in or to any device Controlled by Nektar UK other than those rights granted under Section 2.1 or in or to any device Controlled by any Affiliate of Nektar UK. 
 1.13      “Diligent Efforts” means a level of effort by MAP, its Affiliates and sublicensees, collectively, in performing and carrying out MAP’s obligations
and activities under this Agreement that is consistent with the level of efforts that a commercially reasonable 

  

 3 
 [ *
] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
biopharmaceutical company having resources similar to those of MAP (or, if MAP grants a sublicense under this Agreement including rights to develop and/or
commercialize the Product or if MAP is acquired, having resources similar to those of the party or parties having rights or obligations to perform MAP’s relevant obligations and activities under this Agreement pursuant to such sublicense
agreement or after such acquisition, whether that be MAP or its successor, the sublicensee, and/or the acquirer) would devote to a biopharmaceutical product of similar market, profit and return on investment potential, appropriately taking into
account relevant safety, efficacy, intellectual property, regulatory environment, technical and clinical considerations. 
 1.14      “DMF” means, as the case may be, either a Drug Master File or a Device Master File maintained with the FDA and the equivalent thereof, if any, in jurisdictions outside the
United States. 
 1.15      “EMEA” means the European Medicines Evaluation Agency, or
any successor thereto, which coordinates the scientific review of human pharmaceutical products under the centralized licensing procedure in the European Union. 
 1.16      “FDA” means the United States Food and Drug Administration, or any successor thereto, having the administrative authority to regulate the marketing of
human pharmaceutical products or biological therapeutic products, delivery systems and devices in the United States. 
 1.17      “Field” means administration of the Formulation by nasal or pulmonary delivery to patients by means of a Device. 
 1.18      “Formulation” means any mixture, blend or solution of the Particulate Formation of
Compound, combined with excipients and/or adjuvants (herein referred to from time to time as “processing”) as required for administration by inhalation to a patient using a Device, which mixture, blend or solution has been developed by, on
behalf of or at the direction of, MAP. 
 1.19      “FTE” means the number of days per
year in which the obligations/responsibilities set forth herein will be performed. The current FTE is calculated as [ * ] days per year. 
 1.20      “FTE Rate” means the annual FTE rate of NEKTAR UK, the methodology for which is consistent with NEKTAR UK’s methodology for other similar programs,
and which for 2006 is [ * ], and for each calendar year commencing with the year 2007 shall be adjusted to reflect any year-to-year increase in NEKTAR UK’s actual costs, provided that any increase in the FTE Rate shall not
result in an increase greater than the Consumer Price Index for the San Francisco Bay Area (CPI) (based on a cumulative index of CPI numbers starting on the Effective Date to the date of the calculation of such FTE Rate). NEKTAR UK shall notify MAP
of any adjustment in the FTE Rate for any year on or before December 1 of the preceding year. 
  

 4 
 [ *
] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 1.21      “Good Clinical Practices” or
“GCP” means the then-current standards, practices and procedures set forth in the guidelines entitled in “Good Clinical Practice: Consolidated Guideline,” including related regulatory requirements imposed by the FDA, any
successor agency and as applicable the equivalent thereof in jurisdictions outside the United States. 
 1.22      “Good Manufacturing Practices” or “GMP” means the then-current regulations set forth in 21 C.F.R. Parts 210 – 211, 820 and 21 C.F.R. Subchapter C (Drugs),
Quality System Regulations and the requirements thereunder imposed by the FDA and, as applicable, the equivalent regulations and requirements in jurisdictions outside the United States. 
 1.23      “Information” means formulas, practices, procedures, processes, methods, knowledge,
know-how, trade secrets, skill, experience, documents, apparatus, results, clinical and regulatory strategies, test data, including pharmacological, toxicological and clinical test data, analytical and quality control data, manufacturing data and
descriptions, patent and legal data, market data, financial data or descriptions, devices, assays, chemical formulations, specifications, compositions of matter, product samples and other samples, physical, chemical and biological materials and
compounds, and the like, whether or not patentable. 
 1.24      “MAA” means a
marketing approval application filed with the EMEA for regulatory approval to market and sell Product in the European Union and similar in purpose to the NDA in the United States. 
 1.25      “Major Market Country” means any of the [ * ]. 
 1.26      “MSE” means the manufacturing skid and equipment owned by NEKTAR UK as of the Effective
Date that as of the Effective Date is in place at [ * ] in [ * ]. 
 1.27      “Net Sales” means the dollar amount invoiced by MAP or its Affiliates or sublicensees for sales of the Product to Third Parties (including without limitation to retailers,
distributors, wholesalers, physicians’ offices, hospitals and pain clinics, and expressly excluding Affiliates and sublicensees of MAP) less: (a) customary trade and quantity discounts actually allowed and taken; (b) allowances
actually given for returned or rejected Product; (c) the lesser of (i) [ * ] of the aggregate gross amount invoiced on account of sales of the Product by MAP or a sublicensee to a Third Party in a particular country during
the relevant calendar quarter in respect of which royalties are being calculated or (ii) the actual amount of any write-offs for bad debt relating to such sales of the Product in such country during the relevant calendar quarter in respect of
which royalties are being calculated; (d) freight and insurance, if included in the price; (e) government-mandated and other rebates; and (f) value added tax, sales, use or turnover taxes, excise taxes and customs duties included in
the invoiced price. 
 1.28      “NDA” means (a) the single application or set of
applications for the Product and/or pre-market approval to manufacture and sell commercially both a Formulation, which is, or was processed using, the Particulate Formation of Compound, and a Device, filed by MAP or its sublicensee with the FDA or
any successor agency having the administrative authority to regulate the approval for marketing of new human pharmaceuticals or biological 

  

 5 
 [ *
] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
therapeutic products, delivery systems and devices in the United States and (b) any related registrations with or notifications to the FDA. 

1.29      “Particulate Formation of Compound” means particles of Compound that have been
engineered using NEKTAR UK Core Technology. 
 1.30      “Patent” means
(i) letters patent and utility models including any extension, substitution, registration, confirmation, reissue, re-examination, renewal, or foreign corresponding rights thereof and (ii) to the extent rights are granted by a governmental
authority thereunder, a Patent Application. 
 1.31      “Patent Application” means an
application for letters patent, including without limitation a continuation application, a continued prosecution application, a continuation in-part application or, divisional application, or foreign equivalents thereof. 
 1.32      “Product” means the combination of the Formulation, produced through processing of the
Particulate Formation of Compound, and a Device, the manufacture, use, import, export, offer for sale or sale of which by or on behalf of MAP would, but for the grant of the licenses in Section 2.1, infringe any NEKTAR UK Patent Rights or
exploit any NEKTAR UK Know-How. 
 1.33      “Regulatory Approval” means (a) in
the United States, approval by the FDA of an NDA or other applicable filing and satisfaction of any related applicable FDA registration and notification requirements (if any) and (b) in any country other than the United States, e.g., Europe,
approval by regulatory authorities having jurisdiction over such country, e.g., EMEA, of a single application or set of applications comparable to an NDA or other applicable filing, e.g., MAA, and satisfaction of any related applicable regulatory
and notification requirements, if any, together with any other approval necessary to manufacture and sell pharmaceuticals commercially in such country. 
 1.34      “Regulatory Authority” means the FDA or any successor agency in the United States, and the equivalent regulatory authorities in other jurisdictions of
the Territory, e.g., EMEA. 
 1.35      “MAP Know-How” means all Information that is
(a) owned or otherwise Controlled by MAP at any time during the term of this Agreement, and (b) necessary or useful in developing or manufacturing the Product. MAP Know-How does not include MAP Patent Rights. 
 1.36      “MAP Patent Rights” means the rights granted by any governmental authority under a Patent
that covers a composition, including but not limited to the Formulation, Device, method (including, without limitation, a process or use), apparatus, or manufacture necessary or useful in developing or manufacturing the Product, which Patent is
owned or otherwise Controlled by MAP and covers an invention made before or during the term of this Agreement. MAP Patent Rights do not include MAP Know-How. 
  

 6 
 [ *
] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 1.37      “Territory” means worldwide. 

1.38      “Third Party” means any person or entity other than MAP, NEKTAR UK, a sublicensee of
MAP or an Affiliate of any of them. 
 1.39      “Valid Claim” means either: (a) a
claim of an issued and unexpired patent that has not been (i) cancelled, (ii) declared invalid by an unreversable and unappealable decision of a court or other appropriate body of competent jurisdiction, (iii) admitted to be invalid
or unenforceable through reissue, disclaimer or otherwise, or (iv) abandoned; or (b) a claim of a pending patent application filed and kept pending in good faith and that has not been (i) cancelled, (ii) withdrawn from
consideration, (iii) finally determined to be unallowable by the applicable governmental authority (and from which no appeal is or can be taken), or (iv) abandoned. 
 1.40      “Laws” means any local, state or federal rule, regulation, statute or law in any
jurisdiction relevant to the activities undertaken pursuant to this Agreement or applicable to either of the Parties with respect to any matters set forth herein. 
 1.41      “WPCE” shall mean the Work Plan and Cost Estimate to be developed by the Joint Project Team pursuant to Section 3.6. 
 2.      LICENSE GRANTS 
 2.1      Licenses to MAP. 
 (a)      License to Compound-Inclusive Claims. Subject to the terms and conditions of this Agreement, NEKTAR UK hereby grants MAP an exclusive royalty-bearing license in the
Territory, for the term of this Agreement, with the right to grant sublicenses to the extent permitted under Section 2.3, to and under the Compound-Inclusive Claims and the NEKTAR UK Know-How, to manufacture, use, import, export, offer for
sale, sell and otherwise develop and commercialize the Product within the Field. 
 (b)      License to
Compound-Limited Claims. NEKTAR UK hereby grants MAP a worldwide, exclusive, perpetual, irrevocable, royalty free, fully-paid up license, with the right to grant sublicenses through multiple tiers without restriction, to and under the NEKTAR UK
Patent Rights that are Compound-Limited Claims. The license grant under this Section 2.1(b) shall survive termination or expiration of this Agreement for any reason. For clarity, MAP shall have no milestone obligations under Section 6.1 or
royalty or other payment obligations under Section 6.2 for a Product for which the manufacture, use, import, offer for sale or sale by MAP would, but for the licenses granted pursuant to this Section 2.1, infringe one or more
Compound-Limited Claims that are Valid Claims but would not infringe any Compound-Inclusive Claims that are Valid Claims. 
 2.2      License to NEKTAR UK. MAP hereby grants to NEKTAR UK a nonexclusive, royalty-free license in the Territory under MAP Patent Rights and MAP Know-How solely to the extent useful or necessary for
NEKTAR UK to fulfill its obligations under this 

  

 7 
 [ *
] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
Agreement. In no event shall NEKTAR UK use the MAP Patent Rights or the MAP Know-How for purposes not related to NEKTAR UK’S obligations under this
Agreement. The license granted to Nektar UK by MAP under this Section 2.2 shall terminate on the termination or expiration of this Agreement. 
 2.3      Sublicense Rights. Any sublicensee to whom MAP sublicenses rights under this Agreement, to the extent sublicensing is permitted under this Agreement, shall agree to be bound by all of the
applicable terms and conditions of this Agreement. If MAP desires to sublicense any of the rights granted to it under Section 2.1(a), MAP must obtain the prior written consent of NEKTAR UK, such written consent not to be unreasonably withheld,
except that MAP may grant a sublicense to a Third Party if such Third Party will be responsible for co-developing or commercializing the Product without NEKTAR UK’s prior written consent. MAP’s grant of any sublicense shall not relieve MAP
from any of its obligations under this Agreement, and MAP shall remain jointly and severally liable for any breach of a sublicense by a sublicensee to the extent that such breach would constitute a breach of this Agreement and any breach of the
sublicense by the sublicensee shall be deemed a breach of this Agreement by MAP to the extent that such breach would constitute a breach of this Agreement. 
 2.4      No Implied Rights or Licenses. Neither Party grants to the other any rights or licenses in or to any patent or other intellectual property right, whether by implication,
estoppel or otherwise, except to the extent expressly provided for under this Agreement. Other than as expressly provided for herein, MAP may not copy, distribute, reverse engineer (by way of example but not limitation, by performing tests such as
HPLC, gas chromatography or x-ray crystallography), sell, lease, license or otherwise transfer, modify, adapt or create derivatives of the Particulate Formation of Compound. Other than as expressly provided for herein, NEKTAR UK may not copy,
distribute, reverse engineer (by way of example but not limitation, by performing tests such as HPLC, gas chromatography or x-ray crystallography), sell, lease, license or otherwise transfer, modify, adapt or create derivatives of any Device or the
Formulation. 
 2.5      Exclusivity Covenant. Subject to MAP complying with its obligations to use
Diligent Efforts pursuant to Section 2.6, during the term of this Agreement, NEKTAR UK will not, either alone or in combination with Third Parties, research, develop, or commercialize particles of Compound that have been engineered using NEKTAR
UK Core Technology for inhalation by nasal delivery or pulmonary delivery by means of an inhalation device, except pursuant to this Agreement. For clarity, nothing shall preclude NEKTAR UK or its Affiliates from researching, developing,
manufacturing or commercializing, either alone or in combination with Third Parties, any other products containing Compound, including without limitation, products utilizing pegylation technologies or other pulmonary delivery or nasal delivery
technologies other than NEKTAR UK Core Technology. 
 2.6      Diligence. 
 (a)      Obligations. 
  

 8 
 [ *
] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 (i)      MAP shall use Diligent Efforts to (A) develop,
manufacture and commercialize the Product for use in the Field; and (B) achieve the following diligence milestones with respect to the Product within the time periods set forth below, which time periods may be revised from time to time by the
Parties as defined in Section 2.6(b): 
  

					
	 Commencement of the first Phase
 II clinical
trials*
	 		  	Within [ * ] after the initiation* of the Phase I clinical trials.
			
	 Commencement of the first Phase
 III clinical
trials*
	 		  	Within [ * ] after the initiation* of the Phase II clinical trials.
			
	 First filing of an NDA, MAA or equivalent
 application
for marketing approval in a Major
 Market Country
	 		  	Within [ * ] after completion** of the Phase III clinical trials.
			
	 First Commercial Launch in a
 Major Market
Country
	 		  	Within [ * ] after the first Regulatory Approval in a Major Market Country.

 * With respect to this Section 2.6, a clinical trial or study is deemed to commence on
initial dosing of the first patient or subject in such trial or study. 
 ** With respect to this Section 2.6, a clinical trial or study
is deemed to be complete on the earlier of [ * ] after the final dosing of a patient or subject in such trial or study, or the date of the final report for such trial or study. 
 (ii)      Following the first Commercial Launch of the Product in a Major Market Country and subject to the
limitations of Section 2.6(b), MAP will also use commercially reasonable efforts to commercialize the Product in all other Major Market Countries, and in all other countries in the Territory selected by MAP for commercialization. 
 (iii)      On or before each January 1 during the term of this Agreement until Commercial Launch of the
Product has occurred in a Major Market Country, MAP will provide NEKTAR UK with a written report outlining its progress, and expected timelines to achieve each milestone stated in Sections 2.6(a)(i). In addition, MAP agrees to notify Nektar UK in
writing on the achievement of any milestone event specified under this Section 2.6(a)(i) or Section 6.1. Failure to provide any such written report or written notification under this Section 2.6(a)(iii) by MAP shall not be considered
a material breach of this Agreement unless, following written notification by NEKTAR UK to MAP of MAP’s failure to provide any written report, MAP fails to cure such failure within thirty (30) days of such notice. Notwithstanding anything
in this Section 2.6(a), any failure by MAP to timely pay any amounts due under Section 6.1 shall be a material breach of this Agreement. 
 (b)      Limitations. Although MAP shall at all times be obligated to use Diligent Efforts under Section 2.6(a), if MAP is unable to achieve in a timely manner the milestones in
Section 2.6(a)(i) despite using Diligent Efforts to do so due to factors (including regulatory issues) that are out of the reasonable control of MAP, then pursuant to Section 2.6(c), 

  

 9 
 [ *
] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
the Parties shall agree in good faith to reasonable extensions of the specified dates of completion for the milestones (and shall amend
Section 2.6(a)(i) accordingly) by the amount of the delay caused by such factors. Notwithstanding any other provision of this Section 2.6, MAP’s diligence obligations under Section 2.6(a)(i), including MAP’ s obligation to
meet the milestones set forth in Section 2.6(a)(i), are conditioned upon the absence of any material adverse condition or event related to the safety, bioavailability or efficacy of the Product, significant change in applicable government
regulatory requirements, the occurrence of an act of Force Majeure, impediments caused by engineering of particles, manufacturing or other technical issues related to the Particulate Formation of Compound, or impediments caused by engineering,
manufacturing or other technical issues related to the Compound, Formulation, Device or Product. In addition, each of MAP’s diligence obligations under Section 2.6(a)(i) is also conditioned upon the timely and complete performance by
NEKTAR UK in the performance of its related responsibilities, if any. 
 (c)      Notification and Process
for Amended Diligence Milestones. If MAP believes it will not able to meet any of its obligations under Section 2.6(a)(i) for whatever reason, MAP shall promptly notify NEKTAR UK in writing of such circumstances, including whether
MAP’s inability to meet its obligation under Section 2.6(a)(i) is due to any reason specified in Section 2.6(b). If MAP is unable to achieve the specified completion dates for any milestones under Section 2.6(a)(i) for any reason
specified in Section 2.6(b), the Parties shall agree in good faith to reasonable extensions of the specified dates of completion for the milestones (and shall amend Section 2.6(a) accordingly) by the amount of the delay caused by such
factors. If MAP is unable to meet its obligations under Section 2.6(a)(i) for any reason other than ones specified in this Section 2.6(b), then NEKTAR UK shall not be obligated to discuss or agree to extend any timeframe and shall have the
right (but not the obligation) to terminate this Agreement under Section 14.3. 
 3.      MANUFACTURING 
 3.1      General Background. NEKTAR UK has developed a process to manufacture the Particulate Formation of Compound, using the NEKTAR UK Core Technology, for pulmonary delivery of the Compound by
inhalation. 
 3.2      MSE Transfer. NEKTAR UK hereby transfers to MAP, at no cost to MAP all right,
title and interest of NEKTAR UK in and to the MSE, with the MSE to be located at its current location at [ * ] in [ * ] upon transfer. NEKTAR UK represents that, as of the time of such transfer, it is transferring
to MAP good and marketable title, free of any liens or other encumbrances, in the MSE, but otherwise transfers such equipment “as is” and “where is” and without any other warranty of any kind, whether express, implied or
statutory, including without limitation any warranty of merchantability, fitness for a particular purpose or non-infringement. NEKTAR UK will within ten (10) days of the Effective Date provide MAP with documentation of such transfer as
reasonably requested by MAP. NEKTAR UK shall be responsible for any rent, costs or other obligations prior to the Effective Date with respect to the MSE. As of the Effective Date, MAP will be solely responsible for the MSE and for all liabilities
associated with the MSE. MAP will be solely responsible, at its own expense, for developing, processing and manufacturing (i) the Particulate Formation of Compound on such equipment at [ * ], (ii) the 

  

 10 
 [ *
] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
Formulation using the Particulate Formation of Compound, (iii) any Device, and (iv) the Product (i.e., the combination of the Formulation and a
Device), and for obtaining and maintaining Regulatory Approvals for and commercializing the Product in the Territory. MAP shall manufacture, store, handle, transport and dispose of any wastes relating to the Formulation, any Device and the Product,
in accordance with Laws including without limitation GMP requirements, shall conduct all human clinical trials for the Product in accordance with Laws including without limitation GCP, and shall distribute, market and promote the Product in the
Territory in accordance with Laws. 
 3.3    Responsibilities of the Parties. 
 (a)      If MAP desires that then-current employees of NEKTAR UK perform any of the following for MAP: 

(i)      providing MAP with all technical specifications and materials reasonably requested by MAP to support
manufacturing and scale-up of Particulate Formation of Compound; 
 (ii)      providing MAP with
technical assistance to support scale-up and manufacturing of Particulate Formation of Compound at MAP’s expense at NEKTAR UK’s then current FTE rates plus expenses under Section 3.4; and 
 (iii)      cooperating with MAP in its regulatory filings, including providing any technical information for
regulatory filings that MAP reasonably requests and sending an appropriate representative as needed to meetings with the FDA and EMEA as requested by MAP; 
 then MAP may so notify NEKTAR UK, upon which the Parties will discuss such potential provision of such services by NEKTAR UK to MAP for payment by MAP to NEKTAR UK at the applicable FTE Rate, provided, however, that MAP will
not be obligated to pay for, and NEKTAR UK will not be obligated to provide, any such services other than on terms to which the Parties mutually agree and that no such services shall continue beyond the first anniversary of the Effective Date.

 (b)      At MAP’s request made on or before August 1, 2006, NEKTAR UK will use
commercially reasonable efforts for a period of two (2) months to facilitate MAP’s engagement of former NEKTAR UK employees, either as employees or contractors, for purposes of providing technical assistance to support scale up and
manufacturing of the Particulate Formation of Compound at MAP’s sole expense, provided, however, that MAP will at all times have primary responsibility for negotiation and consummation of such engagement. 
 (c)      MAP’s responsibilities include but are not limited to: 
 (i)      developing and manufacturing [ * ] for use in [ * ]; 
 (ii)      developing, processing and manufacturing [ * ] for use in [ * ];

  

 11 
 [ *
] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 (iii)      designing and managing [ * ];

 (iv)      designing and managing [ * ]; 
 (v)      assembling [ * ] for the Product and managing [ * ] in the Territory;

 (vi)      processing, manufacturing and packaging [ * ] into
[ * ]; and 
 (vii)      commercializing [ * ]. 
 3.4      Access to Information and Standard of Performance. 
 (a)      Sharing of Information. 
 (i)      NEKTAR UK shall provide to MAP within thirty (30) days of the Effective Date, at no cost to MAP, all documents and information specified in Exhibit 3.3(a) that are
possessed by NEKTAR UK as of the Effective Date. For any such documents and information that NEKTAR UK does not possess as of the Effective Date, it shall provide a written statement to MAP stating such fact. 
 (ii)      Until the first anniversary of the Effective Date, as reasonably requested by MAP, NEKTAR UK shall make
available to MAP, at no cost to MAP, any specific NEKTAR UK Know-How that is in documentary form and possessed by NEKTAR UK as of the date of such request, solely for the purpose of enabling MAP to exercise its rights under the license granted
pursuant to Section 2.1; provided, however, NEKTAR UK is not obligated to disclose any NEKTAR UK Know-How that is not reasonably necessary for such purposes. 
 (iii)      Until the third anniversary of the Effective Date, as reasonably requested by MAP, NEKTAR UK will use
commercially reasonable efforts to locate and make available to MAP, at no cost to MAP, any specific NEKTAR UK Know-How that is in documentary form, possessed by NEKTAR UK as of the date of such request, and that the FDA, the EMEA, or an equivalent
governmental authority with jurisdiction in a Major Market Country require under applicable laws or regulations in order to obtain or maintain approval of an NDA, an MAA, or an equivalent marketing approval in a Major Market Country. 
 (b)      Standard of Performance. MAP, in performing its research and development activities and any other
activities in connection with its performance of its obligations in this Agreement, and NEKTAR UK, to the extent it is obligated to perform any activities under this Agreement, shall comply with all Laws including GCP and GMP as applicable.

 (c)      Subcontracting Permitted. NEKTAR UK acknowledges and agrees that portions of the work to be
performed by MAP under this Agreement may be performed on behalf of MAP by Third Parties, at MAP’s sole discretion, provided that MAP 

  

 12 
 [ *
] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
shall first have obtained written confidentiality agreements with any such subcontractors at least as protective as those of Article 11 of this Agreement.
Also, each Party will use reasonable efforts to obtain from such Third Parties written assignments of, or equivalent rights under, all patent rights and know-how that such Third Parties may develop by reason of work performed under this Agreement,
and will bear any and all costs associated with obtaining such assignments. 
 3.5      SMP Line Purchase
Option. MAP shall have an exclusive option to negotiate with NEKTAR UK for the purchase of the existing SMP manufacturing line located at NEKTAR UK’s facilities as of the Effective Date (“SMP Line”), as set forth in this
Section 3.5. If at any time prior to the second anniversary of the Effective Date, NEKTAR UK either receives a bona fide written offer from a Third Party to purchase the SMP Line, or MAP in its sole discretion desires to purchase the SMP Line,
such Party will so notify the other Party. For sixty (60) days from the date of receipt of such written notice, or for such longer period of time as the parties may mutually agree in writing, the Parties will negotiate in good faith a
commercially reasonable price at which MAP may purchase the SMP Line from NEKTAR UK, provided that MAP shall have the right to match the amount of any bona fide written offer triggering such negotiation period. NEKTAR UK shall provide a copy of any
such bona fide written offer to MAP, with the name and any other identifying information of the party making such offer redacted. MAP, by giving written notice to NEKTAR UK, may transfer its rights under this Section 3.5 to its sublicensee of
Particulate Formation of Compound manufacturing rights under the license granted in Section 2.1. If, following any such good faith negotiation between the Parties, they do not reach agreement for MAP’s purchase of the SMP Line and NEKTAR
UK does not sell the SMP Line to the relevant Third Party, MAP’s option under this Section 3.5 shall continue under the terms of this Section 3.5. 
 3.6      Program Management. To plan and manage any regulatory, process development and manufacturing scale up activities conducted pursuant to Section 3.3(a), if any, the
Parties shall appoint a Joint Project Team. Implementation of the Work Plan Cost Estimate (or “WPCE”, as more fully described in Section 3.7) and the specific contracted activities shall be managed by the Joint Project Team.
The Joint Project Team shall be comprised of appropriate representatives of both parties, and shall meet no less frequently than once a month in person or by teleconference when any such work under a WPCE is undertaken. Each Party shall appoint a
project team leader (and other key contacts, as necessary) to serve as principal Joint Project Team liaisons for the Parties. Employees of each Party who are not on the Joint Project Team may attend meetings of the Joint Project Team, as required to
further the Project. Any disagreements between NEKTAR UK and MAP representatives at the Joint Project Team level shall be subject to the dispute resolution procedures as set forth in Article 16. 
 3.7      Work Plan and Cost Estimate. Any specific regulatory, process development and manufacturing scale up
activities to be performed by NEKTAR UK pursuant to Section 3.3(a) and the applicable timelines and budgets for such activities shall be defined for applicable time period during which such activities are to be undertaken in a detailed WPCE
approved in writing by the Joint Project Team. The Joint Project Team will be responsible for the development and implementation of the WPCE. NEKTAR UK, by giving written notice to MAP, may implement changes of [ * ] to the cost
estimate portion of the WPCE; all other changes to 

  

 13 
 [ *
] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
the WPCE shall be subject to prior review and unanimous written approval by the Joint Project Team. 
 3.8      [ * ] Agreement. Upon fulfillment of the NEKTAR UK purchase orders issued to [ * ]
Inc. (“[ * ]”) or its affiliate for critical process parameter work (which does not include any [ * ]) (Purchase Order Nos. [ * ], [ * ], [ * ] and
[ * ]), a [ * ] study (Purchase Order No. [ * ]), and [ * ] (Purchase Order No. [ * ]), in each case for Particulate Formation of Compound, NEKTAR UK shall timely
pay the corresponding invoices that [ * ] Inc. or its affiliate issue, provided that such fulfillment and invoices comply with the terms and provisions of the Services Agreement made and entered into as of [ * ], by
and between NEKTAR UK and [ * ] (“[ * ] Agreement”), and MAP shall pay invoices issued by NEKTAR UK with respect to amounts so paid to [ * ] or its affiliate within thirty (30) days
of MAP’s receipt of such invoices. At any time on or after NEKTAR UK has fulfilled its obligations to fulfill in accordance with the Prior Agreement the MAP issued purchase orders in effect as of the Effective Date for critical process
parameter work (but excluding any portion of such purchase order for [ * ]), a [ * ] study and [ * ] and NEKTAR UK has paid such [ * ] invoices, NEKTAR UK has the right to terminate
the [ * ] Agreement, and if it does so, it shall given written notice of such termination to MAP. 
 4.      REGULATORY FILINGS. 
 4.1      Preparation of Regulatory Filings. MAP is solely responsible for preparing, filing, and maintaining, and shall own, the regulatory filings relating to the Product as set forth in this
Section 4.1. MAP shall, at its election, prepare and maintain Drug or Device Master Files (as the case may be) covering the Formulation, including the Particulate Formation of Compound, and a Device. MAP (or its sublicensee) shall be
responsible for preparing the regulatory submissions for, and obtaining and maintaining, all Regulatory Approvals in the Territory. MAP, as the owner of such Regulatory Approvals is responsible for all interactions with Regulatory Authorities
relating thereto. NEKTAR UK shall cooperate with MAP in the preparation and maintenance of such regulatory submissions and Regulatory Approvals pursuant to Section 3.4(a) and if and to the extent agreed pursuant to Section 3.3(a)(iii).

 4.2      Adverse Reaction Reporting and Product Complaints. To the extent permitted by law, MAP shall
notify the other in writing of all information that comes to its attention concerning serious adverse events in connection with the Product that are or may be reasonably attributable to the Particulate Formation of Compound, rather than to the
Product generally or to the Compound. 
 5.      PACKAGING; NEKTAR UK
MARK. 
 5.1      Packaging. To the extent allowable by law and upon written request
by NEKTAR UK, the Product packaging shall carry the trademark, trade name, brand name, logo or other marking of NEKTAR UK or its permitted assignee under Section 17.2 (subject to grant of an appropriate, royalty-free license to MAP by such
assignee reasonably consistent with that granted by NEKTAR UK in Article 13), the identity and style of which shall be subject to MAP’s reasonable approval of the size, position, and location thereof on such Product packaging. Such trademark,
trade name, brand name, logo or other marking of NEKTAR UK or 

  

 14 
 [ *
] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
its permitted assignee will be in addition to the trademarks, brand name, trade name, logos and company name of MAP. Further, such Product packaging, package
inserts and any promotional materials associated with the Product, will carry, in a conspicuous location, a patent notice in accordance with and when required by the applicable laws of the country in which (a) the Product is sold and (b) a
claim in a patent included in the NEKTAR UK Patent Rights covering the Product exists, with the size, placement, positioning and location of such patent markings being determined by mutual agreement of the Parties. Nothing in this Section 5.1
shall be construed as a consent by MAP to any such assignment of this Agreement by NEKTAR UK under Section 17.2. 
 6.      PAYMENT OBLIGATIONS. 
 6.1      Milestone Payments. In addition to the amounts due to NEKTAR UK pursuant to Section 6.2, in partial consideration for the grant of the license by NEKTAR UK to MAP under Section 2.1(a),
MAP shall make the following non-refundable, non-creditable milestone payments (the “Milestone Payments”) to NEKTAR UK with respect to this Agreement and the Product within [ * ] after achievement of the relevant
milestone: 
  

			
	Milestone Event	  	Milestone
Payment Amount
(U.S. Dollars)
		
	(A)    Completion of first Phase II human clinical trial*.	  	[ * ]
		
	(B)    Filing of the first NDA, MAA or equivalent application for marketing approval for the Product.	  	[ * ]
		
	(C)    The First Commercial Launch of the Product in the first of the Major Market Countries.	  	[ * ]
		
	(D)    The date (or, if the effective date is before the date on which such parties enter such agreement, then such entry date) of any agreement between MAP or any of its
Affiliates and a Third Party under which MAP or any such Affiliate (i) grants a sublicense under its license in Section 2.1(a) that includes the right to commercialize the Product or (ii) grants rights to market, promote, distribute
and/or sell the Product, in each case the effective date (or, as applicable, the entry date) of such agreement being prior to the completion of the first Phase III human clinical trial of the Product, provided however, that the grant of an
unexercised option, for a cumulative period of no more than three (3) years, to receive a grant as described in clauses (i) or (ii) shall not be a milestone event under this clause (D), subject to Section 6.2(e) as
applicable*.	  	[ * ]
		
	(E)    The effective date (or, if the effective date is before the date on which such parties enter such agreement, then such entry date) of any	  	[ * ]

  

 15 
 [ *
] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

			
	agreement between MAP or any of its Affiliates and a Third Party under which MAP or any such Affiliate (i) grants a sublicense under its license in Section 2.1(a) that includes the right to
commercialize the Product or (ii) grants rights to market, promote, distribute and/or sell the Product, in each case the effective date (or, as applicable, the entry date) of such agreement following the completion of the first Phase III human
clinical trial of the Product, provided however, that the grant of only an unexercised option, for a cumulative period of no more than [ * ], to receive a grant as described in clauses (i) or (ii) shall not be a milestone event under this
clause (E) subject to Section 6.2(e) as applicable*.	  	

 * For purposes of this Section 6.1, a human clinical trial shall be deemed to be complete upon the earlier of
issuance of the final report regarding such clinical trial by or on behalf of MAP, its Affiliates or sublicensees, (ii) with respect to a Phase II clinical trial, [ * ] after the final dosing of the last patient in such
clinical trial, and (iii) with respect to a Phase III clinical trial [ * ] after the final dosing of the last patient in such clinical trial. 
 6.2    Royalties and Alternate Payments. 
 (a)      Under the terms and conditions of this Agreement, in partial consideration for the grant of the license under NEKTAR UK to MAP under Section 2.1(a), MAP shall pay NEKTAR UK a royalty on a
quarterly basis, which royalty is based on Net Sales per annum of the Product sold in the Territory by MAP or its Affiliates or sublicensees, in which, and for so long as, the manufacture, use, import, export, offer for sale, or sale of such Product
is covered by a Valid Claim of NEKTAR UK Patent Rights that is a Compound-Inclusive Claim: 
  

					
	Royalty Rate	 		  	Net Sales in the Territory (Per Annum)
			
	[ * ]	 		  	Less than or equal to [ * ] 
			
	[ * ]	 		  	Greater than [ * ] and less than or equal to [ * ] 
			
	[ * ]	 		  	Greater than [ * ] 

 As an illustrative example of the royalty scheme under this Section 6.2(a), if Net Sales of the Product by
MAP for a given year amount to [ * ], NEKTAR UK will receive a royalty of [ * ] of the first [ * ] of Net Sales (equal to [ * ] ), a royalty [ * ] on the next
[ * ] of Net Sales (equal to [ * ]), and royalty of [ * ] on the final [ * ] of Net Sales (equal to [ * ]), for a total royalty of [ * ].

 (b)      In the event that there is no Valid Claim of NEKTAR UK Patent Rights that is a
Compound-Inclusive Claim covering the manufacture, use, import, export, offer for sale or sale of the Product in a particular country, then the royalty due under Section 6.2(a) shall be reduced by [ * ] for such particular
country based on the total blended royalty calculated for the Territory in Section 6.2(a) from and after the first sale of a Product in such country which is not covered by a Valid Claim of the NEKTAR UK Patent Rights that is a
Compound-Inclusive 

  

 16 
 [ *
] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
Claim covering the manufacture, use, import, export, offer for sale or sale of the Product in a such country until the termination until the obligation of
MAP to pay royalties ceases as specified in Section 14.1. The obligations of MAP to pay reduced royalties under this Section 6.2(b) shall be determined as set forth in Section 14.1. 
 (c)      If MAP or any of its Affiliates grants a sublicense that includes the right to commercialize the Product
under this Agreement to a Third Party(ies), or grants a Third Party(ies) rights to market, promote, distribute and/or sell the Product, then: 
 (i)      within ten (10) business days of entry into the agreement pursuant to which any such grant is made, MAP will provide NEKTAR UK an copy of all agreements pursuant to which or in connection
with which such grant was made, provided that MAP may redact any provision that is not a right or obligation under such agreement, 
 (ii)      in place of the milestones and royalties set forth in Sections 6.1 and 6.2(a), but subject to Section 6.2(e), MAP shall pay NEKTAR UK [ * ] of all of the
[ * ] incurred by MAP, its Affiliates or its sublicensees (other than such Third Party) for [ * ] of MAP, its Affiliates or sublicensees (other than such Third Party), any [ * ] extended to MAP, its
Affiliates or sublicensees (other than such Third Party), and any [ * ] incurred by MAP, its Affiliates or its sublicensees (other than such Third Party) received in consideration of the grant(s) of such sublicense(s) or other
right(s), in each case that is received by MAP, its Affiliates or its sublicensees (other than such Third Party), and in each case after deduction from such amounts any tax or other government charge (other than income tax) levied on such amounts to
the extent borne by MAP, its Affiliates and sublicensees (such amounts to be paid by MAP, collectively, “Sublicense Revenues”), but in no event shall NEKTAR UK receive, on a country-by-country basis, less than [ * ]
of the aggregate Net Sales per annum of the Product sold in a particular country where such Third Party rights with respect to the Product have been granted by MAP or its Affiliates or sublicensees, and 
 (iii)      any Net Sales made by any such sublicensee shall not be included in the calculation of Net Sales for
which MAP is obligated to pay a royalty pursuant to Section 6.2(a). 
 (d)      If MAP or any of
its Affiliates grants an option as described in milestones (D) or (E) of Section 6.1, MAP will pay NEKTAR UK [ * ] of any amounts received by MAP or its Affiliates in consideration for such grant that, but for being
granted in connection with an option grant, falls within the definition of Sublicense Revenues. For clarity, any amount payable by MAP under this Section 6.2(d) shall be payable only one time and shall be due within thirty (30) days of the
effective date of the first agreement granting such option and no payment regarding such option grant shall be due under Sections 6.1, 6.2(c) or 6.2(e), provided that this sentence does not apply to exercises of any such option grant. 
 (e)      Notwithstanding any provision of Sections 6.1 or 6.2(c), if MAP or its Affiliates enter into any agreement
with a Third Party under which MAP (i) grants a sublicense under its license in Section 2.1(a) that includes the right to commercialize the Product or (ii) grants rights to market, promote, distribute and/or sell the Product, and
under which such 

  

 17 
 [ *
] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
agreement MAP or its Affiliates have the non-contingent right to receive any Sublicense Revenues within ninety (90) days of the effective date (or, if
later, the entry date) of such agreement (“Up-front Sublicense Revenues”), then MAP will pay NEKTAR UK the applicable milestone payment (D) or (E) pursuant to Section 6.1 instead of [ * ] of such
Up-front Sublicense Revenues as set forth in Section 6.2(c), if such milestone is in excess of [ * ] of such Up-front Sublicense Revenues. For clarity, any such milestone payment pursuant to Section 6.1 shall be paid only
one time and shall be due on the Effective Date of the first sublicense. 
 (f)      In addition to
Sections 6.2(b) and 6.2(c), the calculation of Net Sales and royalties under this Section 6.2 shall be subject to the application of ANTI-BUNDLING. “ANTI-BUNDLING” means any or all of the following: 
 (i)      If MAP or its sublicensees receive consideration other than cash for sales of the Product, then the fair
market value of such consideration shall be included in Net Sales. 
 (ii)      If the Product is sold
by MAP or its sublicensees at a price less than would have been obtained in an arm’s length transaction, Net Sales shall be calculated using the average price at which such the Product was sold during the reporting period in which the sale of
the product at a reduced price occurred, provided that the average price will be calculated using aim’s length transactions only. 
 (iii)      If the Product is sold in combination with other products (the combination referred to as a “BUNDLE”) at a price less than the sum of MAP’s or its sublicensees’ average
prices for all of the products included in the BUNDLE (as determined for such products in the immediately preceding reporting period), the gross receipts used for computing the royalty due under this Agreement shall be equal to the price of the
BUNDLE multiplied by the average price for such Product (as determined for such Product in the immediately preceding reporting period) divided by the sum of the prevailing prices for all products included in the BUNDLE if sold separately (as
determined above). 
 (g)      If any Third Party obtains or is granted a Compulsory License in any
country to manufacture, use, import, export, offer for sale, or sell the Product, then MAP and NEKTAR UK (whoever has first notice thereof) shall promptly notify the other Party. If the royalty rate payable by the grantee of the compulsory license
is less than the royalty set forth in Section 6.2(a) for such country, then the royalty payable by MAP hereunder in respect of those sales made under the compulsory license shall be reduced to such lower rate enjoyed by such Third Party grantee
in the subject country if and for so long as the sales made by such Third Party pursuant to the compulsory license in such country exceed [ * ] of MAP’s or its sublicensee’s Net Sales of the Product in such country.

 6.3    Payments. Payments due under Sections 6.2(a) and (b) shall be paid not later than thirty
(30) calendar days following the end of each calendar quarter with respect to Net Sales in such quarter. Royalty payments due NEKTAR UK by MAP as a result of sublicensee payments will be made within thirty (30) calendar days of receipt of
such payments by MAP. Payments due under Section 6.2(c) (other than any [ * ] share of royalties) shall be paid not later 

  

 18 
 [ *
] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
than thirty (30) calendar days after MAP’s receipt of the applicable Sublicense Revenues. Each payment under this Section 6.3 with respect to
royalties or any share thereof shall be accompanied by a written report showing (i) the calendar quarter for which such payment applies, (ii) the amount billed to Third Parties other than sublicensees for Product during such quarter,
(iii) the total deductions from the amount billed to arrive at Net Sales, and (iv) the amount of royalties due. Any late payments under this Agreement shall bear interest at a rate of prime plus [ * ] per annum or the
maximum rate permitted by law, whichever is less. 
 6.4      Currency of Payment. All payments to be
made under this Agreement shall be made in U.S. Dollars. Net Sales outside the United States shall be first determined in the currency of the country in which they are earned and shall be converted quarterly into an amount in U.S. Dollars at the
average of the bid and ask prices reported in the Wall Street Journal as of the close of the last business day of such quarter in which royalty is due. All such converted Net Sales and cost items shall be consolidated with U.S. Net Sales for each
calendar quarter and the applicable payments determined therefrom. 
 6.5      Single Royalty. Royalties
payable under Sections 6.2(a) and (b) and milestones payments payable under Section 6.1 will be payable only once with respect to a particular Product and will be paid only once regardless of there being more than one Patent applicable to
such Product. For clarity, the Parties agree that with regard to a particular Product, in addition to the milestone payments specified in (A), (B) and (C) of Section 6.1, if either of the milestone events specified in (D) or
(E) of Section 6.1 occurs, then only the milestone payment corresponding to the first to occur of such milestone events in (D) or (E) of Section 6.1 shall be due with regard to such Product, subject to Sections 6.2(c),
(d) and (e). 
 6.6      Sublicensing. In the event MAP grants a sublicense under
Section 2.1(a) to a sublicensee to manufacture, use or sell the Product, such sublicenses shall require the sublicensee to (i) account for and report its Net Sales of the Product on the same basis as if such sales were Net Sales of the
Product by MAP to MAP so that MAP may use such information to make payments consistent with the requirements of Section 6.3, (ii) keep records with respect to its activities with the Product to the same extent that MAP is required to do so
pursuant to Sections 7.1 and 7.2, (iii) permit audits by NEKTAR UK of such sublicensee and its records to the same extent that NEKTAR UK may audit MAP and its records pursuant to Section 7.3 and (iv) comply with Section 5.1.

 7.      RECORD KEEPING, RECORD RETENTION
AND AUDITS. 
 7.1      Record Keeping. MAP shall record, to the
extent practical, Information relating to the research, development, processing and manufacture of the Formulation and the Product in standard laboratory notebooks, which shall be signed, dated and witnessed, or if kept electronically, suitably
validated. NEKTAR UK shall record, to the extent practical, Information relating to the research, development, and manufacture of the Particulate Formation of Compound in standard laboratory notebooks, which shall be signed, dated and witnessed, or
if kept electronically, suitably validated. Each Party shall require its employees and consultants to disclose any inventions relating to, in the case of MAP, the Formulation and the Product and, in 

  

 19 
 [ *
] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
the case of NEKTAR UK, the Particulate Formation of Compound, in writing promptly after conception. 
 7.2      Records Retention. MAP shall keep complete and accurate records of its regulatory filings and
commercialization records related to the Product, including without limitation those relating to sublicensing, distribution, promotion, marketing and other commercialization agreements, Product rejection, return or complaint records, invoices,
shipping records or similar documents necessary to confirm MAP’ s performance hereunder. Such records shall also contain sufficient detail to permit NEKTAR UK to confirm the accuracy of calculations of all payments made under Article 6. The
records to be maintained by MAP under this Section 7.2 shall be maintained for a minimum of four (4) years following the year in which the corresponding efforts or payments, as the case may be, were made under this Agreement or longer if
required by regulatory requirements. 
 7.3      Audit Request. NEKTAR UK has, at its expense (except as
provided below), the right to audit, on an annual basis, the records maintained by MAP under Section 7.2, to determine with respect to any calendar year, the accuracy of any report or payment made under this Agreement. If NEKTAR UK desires to
audit such records, it will engage an independent, certified public accountant reasonably acceptable to MAP to examine such records. Such accountant will be instructed to provide to NEKTAR UK a report on the findings of the agreed upon procedures
verifying any report made or payment submitted by MAP during such period, but will not disclose to NEKTAR UK any confidential information of MAP not necessary therefor. The expense of such audit will be borne by NEKTAR UK; provided, however, that if
an error of more than [ * ] is discovered, then such expenses shall be paid by MAP. Such auditors shall not be paid on a contingency basis. Any Information received by NEKTAR UK pursuant to this Section 7.3 is deemed to be
Confidential Information of MAP. 
 7.4      Survival. This Article 7 survives the expiration or any
termination of this Agreement for a period of four (4) years. 
 8.      INVENTIONS,
KNOW-HOW AND PATENTS. 
 8.1      Ownership
of Inventions. Except as otherwise set forth herein, all inventions and discoveries acquired or developed solely by employees of a Party during the course of this Agreement (“Sole Inventions”) are the sole property of such
Party. In the event that employees of MAP and NEKTAR UK jointly develop any invention or discovery, MAP and NEKTAR UK will each own an undivided one-half (1/2) interest, without the consent of or a duty of accounting to the other Party, in and
to such invention (“Joint Invention”), except as otherwise provided herein. With respect to MAP’S Sole Inventions and Joint Inventions relating solely to the NEKTAR UK Core Technology, MAP hereby assigns its entire right, title
and interest in and to such Sole or Joint Invention to NEKTAR UK in consideration for the license granted herein. With respect to NEKTAR UK’S Sole Inventions and Joint Inventions relating solely to a Device and the Formulation, and NEKTAR
UK’S Sole Inventions and Joint Inventions in the Field relating solely to: the Compound or methods of administering the Compound (collectively the “MAP Core Technology”), NEKTAR UK hereby assigns its entire right, title and
interest in and to such Sole Inventions and Joint Inventions to MAP in 

  

 20 
 [ *
] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
consideration for the payment and development obligations of MAP as set forth in this Agreement. In the event any Joint Invention that is jointly owned by
the Parties has applicability outside the Field, each Party has the right to independently manufacture, use, import, export, offer for sale, or sell such Joint Invention, and has the right to assign or sublicense its rights in and to such Joint
Invention, without the consent of or a duty of accounting to the other Party. 
 8.2      Individual Program
Patent Filings. Each Party has sole discretion and responsibility to prepare, file, prosecute and maintain Patent Applications or Patents for its Sole Inventions, Sole Inventions of the other Party which were assigned to such Party under
Section 8.1 and Joint Inventions, which were assigned to such Party under Section 8.1 and shall control all related proceedings. Each Party will endeavor to ensure whenever possible that claims are filed and prosecuted in such Patent
Applications and Patents specifically directed to the Field or solely directed to the Particulate Formation of Compound, a Device or the Formulation, as the case may be. The Parties will endeavor to file such Patent Applications and Patents before
any oral, written or electronic disclosure of the inventions claimed therein by either Party to maintain the validity of Patent Applications filed outside of the United States. At least twenty (20) days prior to the contemplated filing date,
each Party will submit to the other Party a substantially completed draft of any Patent Application arising under this Agreement. Each Party will confer with the other, and make reasonable efforts to adopt the other Party’s reasonable
suggestions regarding the prosecution of such Patent Applications and will copy the other Party on any official actions and submissions in such Patent Applications; however, final decision-making authority in prosecution of a Patent Application will
reside with the Party who owns or was assigned the applicable Sole Invention or Joint Invention claimed in such Patent Application as set forth in Section 8.1. Irrespective of the ultimate ownership of the Patent Applications or Patents, MAP
will bear all costs incurred pursuant to this Section 8.2 for Patent Applications or Patents that are solely applicable to the Field, and NEKTAR UK will bear all costs incurred pursuant to this Section 8.2 for Patent Applications that are
not solely applicable to the Field. Each Party may delegate the preparation filing, and prosecution of Patent Applications and the maintenance of Patents pursuant to this Section 8.2 to a qualified Third Party. 
 8.3      Joint Program Patent Filings. To the extent it is practical to do so, Patent Applications on Joint
Inventions relating solely to the Field or solely directed to the Particulate Formation of Compound, a Device or the Formulation shall be separately defined and prosecuted. With respect to all Patent Applications on Joint Inventions that have not
been assigned to one Party under Section 8.1 (the “Joint Patent Applications”), the Parties will determine which Party is responsible for filing, prosecuting, maintaining and defending patent applications and patents on behalf
of both Parties based on a good faith determination of the relative contributions of the Parties to the invention and the relative level of interest of the Parties in the invention; provided, however, MAP will prosecute, maintain and defend Joint
Patent Applications that solely relate to inventions in the Field. At least twenty (20) days prior to the contemplated filing, the responsible Party will submit a substantially completed draft of the Joint Patent Application to the other Party
for its approval, which will not be unreasonably withheld. Except as otherwise set forth in this Section 8.3, the Parties will share equally the costs of the preparation, filing, prosecution and maintenance of all Joint Patent Applications. If
the Responsible Party does not wish to file, prosecute or maintain any Joint Patent Application or maintain or defend such a Patent in a particular country, it shall grant the other Party any 

  

 21 
 [ *
] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
necessary authority to file, prosecute and maintain such a Patent Application or maintain or defend such a Patent in the name of both Parties. If either
Party elects not to pay its portion of any shared costs for a Joint Patent Application or Patent issuing therefrom, the other Party may proceed with such Joint Patent Application or defense of such Patent in its own name and at its sole expense, in
which case the Party electing not to pay its share of costs will assign its entire right, title and interest in and to such Joint Patent Application to the other Party and such invention is treated as a Sole Invention of the assignee for the
purposes of Sections 8.1 and 8.2. 
 8.4      MAP Improvements to SEDS Technology. MAP, on behalf of it,
its Affiliates, sublicensees, assignees and successor, hereby agrees that it, its Affiliates, sublicensees, assignees and successors will not (a) enforce against NEKTAR UK, its Affiliates, sublicensees, permitted assignees or successors, any
Patents, Patent Applications or other intellectual property rights regarding improvements to the NEKTAR UK Core Technology developed by or on behalf of MAP or its Affiliates, its sublicensees, assignees or successors, during the course of this
Agreement (the “MAP NEKTAR UK Core Technology Improvement IP”) or sue or institute any demand, claim, action, suit or proceeding against NEKTAR UK, its Affiliates or sublicensees under the NEKTAR UK Core Technology, permitted
assignees or successors alleging, claiming or on the basis that there is, any infringement or misappropriation of any MAP NEKTAR UK Core Technology Improvement IP, or (b) facilitate, assist, participate in or cause any third party to so sue or
bring, any such suit, demand, claim, action or proceeding against NEKTAR UK, its Affiliates or sublicensees under the NEKTAR UK Core Technology, permitted assignees or successors. 
 9.      INFRINGEMENT. 
 9.1    Infringement of Third Party Rights. 
 (a)      Notice. If the development, manufacture, use, import, export, offer for sale or sale of the Product (including without limitation through Product development and manufacture, use, import,
export, offer for sale or sale of any intermediate in production of the Product or any portion of the Product, e.g. the Particulate Formation of Compound or Device) results in a claim, demand, suit, action or proceeding by a Third Party for patent
infringement (“Third Party Patent Claim”), the Party to this Agreement first having notice shall promptly notify the other Party in writing. The notice shall set forth the facts of the Third Party Patent Claim in reasonable detail.

 (b)      Conduct of Litigation. MAP, at its sole expense, shall control the defense and/or
settlement of any Third Party Patent Claim, including without limitation, any Third Party Patent Claim that alleges or asserts that the development, processing, manufacture, use, import, export, offer for sale, or sale of the Particulate Formation
of Compound, Formulation, a Device and/or the Product, in each case infringes a Third Party Patent. With regard to a Third Party Patent Claim that asserts the manufacture, use, import, export, offer for sale, or sale of the Particulate Formation of
Compound under the licenses granted in Section 2.1 infringes a Third Party Patent (“Particulate Formation of Compound Claim”), (i) NEKTAR UK shall cooperate with MAP at MAP’s expense and reasonable request in such
defense, has the right to be represented by counsel of its own choice in such defense at its own expense, (ii) MAP 

  

 22 
 [ *
] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
has the sole discretion to settle any such Particulate Formation of Compound Claim where such settlement involves only the payment of money to be made by
MAP, and (iii) if the settlement of any such Particulate Formation of Compound Claim involves anything other than the payment of money to be made by MAP, MAP must obtain NEKTAR UK’s consent in writing to the terms of such settlement
agreement, with such consent not to be unreasonably withheld or delayed. MAP shall have the sole discretion to settle any other Third Party Patent Claim that is not a Particulate Formation of Compound Claim. 
 (c)      Litigation Payments and Costs. If either Party has an obligation to make any payments (including without
limitation any royalty payments and/or one-time or lump sum payments) to a Third Party under a final court order or a pursuant to a settlement into which MAP enters in good faith, in each case as part of the disposition or settlement of a Third
Party Patent Claim, MAP shall make all such payments. Any such payments (including without limitation any royalty payments and/or one-time or lump sum payments) made by MAP as part of disposition or settlement of a Particulate Formation of Compound
Claim shall be “Article 9 Payments”. Any reasonable and documented litigation costs and expenses (including reasonable attorneys’ fees) of MAP incurred in the defense or litigation of a Particulate Formation of Compound Claim
shall be “Article 9 Costs”. MAP shall be entitled to a credit for such Article 9 Payments and Article 9 Costs against royalties payable to NEKTAR UK pursuant to Section 6.2 (including, as applicable, NEKTAR UK’s share of
royalties on Net Sales pursuant to Section 6.2(c)), subject to the following: 
 (i)      up to
[ * ] of Article 9 Payments may be offset against such royalties subject to the following limitations: 
 (A)      if such Article 9 Payments are on the basis of royalties, then the royalties payable by MAP to NEKTAR UK may not be reduced in any quarter by more than [ * ] by reason of such
offset, and no such offset that was not applied due to such limitation may be carried into any subsequent quarter; 
 (B)      if such Article 9 Payments are a one-time lump sum payment, then the royalties payable by MAP to NEKTAR UK may not be reduced in any quarter by more than [ * ] by reason of such
offset; provided, however, that any excess amounts that have not been offset in a particular quarter may be carried into subsequent quarters; and 
 (C)      if such Article 9 Payments are both a one-time lump sum payment and royalty
payments, then MAP will be permitted to offset the royalty portion of any such payments against the royalties owed to NEKTAR UK to the extent provided for in Section 9.1(c)(i)(A), prior to offsetting the lump sum portion of any such payments
against royalties owed to NEKTAR UK to the extent provided for in Section 9.1(c)(i)(B). 
 (ii)      up to [ * ] of such Article 9 Costs may be offset against the royalties that are payable by MAP to NEKTAR UK, subject to the following limitations: the royalties payable by MAP
to NEKTAR UK under this Agreement may not be reduced in any 

  

 23 
 [ *
] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
quarter by more than [ * ] by reason of such offset under this Section 9.1(c)(ii) or Section 9.1(c)(i); provided,
however, that any excess amounts of Article 9 Costs that have not been offset in a particular quarter may be carried into subsequent quarters. 
 (iii)      To avoid doubt, and notwithstanding anything to the contrary in this Agreement, the right of MAP under Section 9.1(c)(i) to offset royalties payable by MAP shall
not be cumulative, such that the total amount of royalties that MAP may offset in any single quarter during the period of time during which royalties are due and payable hereunder, shall in total be no more than [ * ] of the
royalties which otherwise would be due NEKTAR UK under this Agreement on Net Sales of the Product during such quarter. The remedies set forth in this Section 9.1(c) shall be NEKTAR UK’s sole liability, and MAP’s sole remedy, for any
actual or alleged infringement of Third Party Patents as a result of the manufacture, use, import, export, offer for sale, or sale of the Particulate Formation of Compound. 
 (d)      If NEKTAR UK seeks to invoke MAP’s obligation to defend pursuant to this Section 9.1, the
procedures set forth in Section 10.3 shall apply with respect to any obligation to defend that is provided for in this Section 9.1. 
 9.2    Infringement By Third Parties. For purposes of this Section 9.2, Compound-Limited Claims shall be deemed not to be included within NEKTAR UK Patent Rights. 
 (a)      Notice. If any of the NEKTAR UK Patent Rights or NEKTAR UK Know-How in the Field is infringed or
misappropriated by a Third Party, the Party first having knowledge of such infringement or misappropriation shall promptly notify the other Party in writing. The notice shall set forth the facts of such infringement or misappropriation in reasonable
detail. 
 (b)      Prosecution of Actions Related to NEKTAR UK Core Technology. 
 (i)      Subject to Section 9.2(b)(ii), NEKTAR UK has the sole right, but not the obligation, to institute,
prosecute and control any claim, demand, action, suit or proceeding with respect to any actual or potential infringement or misappropriation of any of the NEKTAR UK Patent Rights or NEKTAR UK Know-How arising from the use by a Third Party of NEKTAR
UK Core Technology in the Field, by counsel of its own choice and at its own expense. MAP shall cooperate with NEKTAR UK at NEKTAR UK’s expense and reasonable request in the prosecution of such action or proceeding. If NEKTAR UK reasonably
determines that MAP is an indispensable Party to the action, MAP hereby consents to be joined and to provide all reasonably necessary cooperation. In such event, MAP has the right to be represented in that action by its own counsel and at its own
expense. 
 (ii)      MAP has the first right, but not the obligation, to institute, prosecute and
control any claim, demand, action, suit or proceeding with respect to any actual or potential infringement of any of the NEKTAR UK Patent Rights arising from the use by a Third 

  

 24 
 [ *
] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
Party of NEKTAR UK Core Technology in the Field, where such Patent infringement is or is allegedly due to the manufacture, use, import, export, offer for
sale or sale of a product that is competitive with the Product (“Competitive Product Infringement”), by counsel of its own choice and at its own expense. If MAP fails to bring a claim, demand, action, suit or proceeding for Patent
infringement pursuant to this Section 9.2(b)(ii) within a period of sixty (60) days after receiving written notice from NEKTAR UK or otherwise having knowledge of such infringement or misappropriation of NEKTAR UK Core Technology in the
Field, NEKTAR UK has the right, but not the obligation, to bring and control any such claim, demand, action, suit or proceeding by counsel of its own choice and expense. If a Party bringing any claim, suit, action or proceeding pursuant to its right
under this Section 9.2(b)(ii) that the other Party is an indispensable Party to the claim, suit, action, or proceeding, the other Party hereby consents to be joined, and to provide all requested reasonable cooperation at the first Party’s
expense. In such event, the other Party has the right to be represented in such action by its own counsel at its own expense. No settlement, consent judgment or other voluntary final disposition of a Competitive Product Infringement claim, demand,
suit, action or proceeding may be entered into without the joint consent of MAP and NEKTAR UK (which consent shall not be withheld unreasonably). 
 (c)      Awards. If NEKTAR UK brings a claim, demand, suit, action or proceeding for infringement or misappropriation by a Third Party under Sections 9.2(b)(i), it will retain solely any damages or other
monetary awards recovered by NEKTAR UK. If a Party brings a claim, demand, suit, action or proceeding for infringement or misappropriation by a Third Party under Section 9.2(b)(ii), any damages or other monetary awards recovered by such
controlling Party shall be applied first to defray the costs and expenses of both Parties incurred in the action. The controlling Party shall pay the other Party [ * ] of any balance that remains. 
 9.3    Prosecution of Actions Related to any Device, the Compound or the Formulation. For purposes of this Section 9.3,
Compound-Limited Claims shall be deemed to be included within MAP Patent Rights. 
 (a)      Notice. If
any of the MAP Patent Rights or MAP Know-How in the Field is infringed by a Third Party, the Party first having knowledge of such infringement shall promptly notify the other Party in writing. The notice shall set forth the facts of such
infringement in reasonable detail. 
 (b)      MAP has the primary right, but not the obligation, to
institute, prosecute and control any claim, demand, action, suit or proceeding with respect to any infringement or misappropriation of any of the MAP Patent Rights or MAP Know-How arising from the processing, manufacture, use, import, export, offer
for sale, or sale of a Device, the Compound or the Formulation in the Field, excluding any particulate formations (including but not limited to the Particulate Formation of Compound). If MAP reasonably determines that NEKTAR UK is an indispensable
party to any such claim, action, suit, or proceeding, NEKTAR UK hereby consents to be joined and to provide all reasonable cooperation at MAP’s expense. In such event, NEKTAR UK has the right to be represented in that claim, action, suit, or
proceeding by its own counsel and at its own expense. 
  

 25 
 [ *
] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 (c)      If MAP fails to bring a claim, demand, action, suit or
proceeding against a Competitive Product Infringement under Section 9.3(b) within a period of sixty (60) days after receiving written notice from NEKTAR UK of such actual or potential infringement, or otherwise having knowledge of such
actual or potential infringement described in Section 9.3(a), NEKTAR UK has the right, but not the obligation, to bring and control any such claim, demand, action, suit, or proceeding by counsel of its own choice and expense. If NEKTAR UK
reasonably determines that MAP is an indispensable Party to any claim, action, suit or proceeding, MAP hereby consents to be joined and to provide all reasonable cooperation at NEKTAR UK’s expense. In such event, MAP has the right to be
represented in such claim, action, suit or proceeding by its own counsel at its own expense. No settlement, consent judgment or other voluntary final disposition of a claim, demand, action, suit or proceeding under this Section 9.3(c) may be
entered into without the joint consent of NEKTAR UK and MAP (which consent shall not be withheld unreasonably). 
 (d)      Awards. If MAP brings a claim, demand, action, suit, or proceeding for infringement by a Third Party under Section 9.3(b), any damages or other monetary awards recovered by MAP shall be
applied first to defray the costs and expenses incurred by both Parties in the action. MAP will pay to NEKTAR UK the applicable royalty on Net Sales as calculated under Section 6.2 with respect to any balance that remains, with such balance
being treated as lost profits and the corresponding level of Net Sales being determined from such lost profits. If NEKTAR UK brings a claim, demand, action, suit, or proceeding for infringement by a Third Party under Section 9.3(c), any damages
or other monetary awards recovered by NEKTAR UK shall be applied first to defray the costs and expenses of both Parties incurred in the action, and NEKTAR UK shall then pay MAP any balance that remains less the applicable royalty calculated in
accordance with the immediately preceding sentence. 
 9.4    Other Infringement. NEKTAR UK will retain any and
all rights to pursue in its sole discretion any claim, demand, action, suit, or proceeding against, and control all such relating to, an infringement or misappropriation by or a Third Party of the NEKTAR UK Patent Rights or NEKTAR UK Know-How other
than those addressed in Section 9.2. MAP will retain any and all rights to pursue in its sole discretion any claim, demand, action, suit, or proceeding against, and control all such relating to, an infringement or misappropriation by a Third
Party of the MAP Patent Rights or the MAP Know-How other than those addressed in Section 9.3. 
 9.5    The
Parties’ Representations and Warranties. NEKTAR UK and MAP each hereby represents and warrants to the other that, to the best of such Party’s knowledge as of the Effective Date: 
 (a)      It has sufficient legal and/or beneficial title under its intellectual property rights necessary for the
purposes contemplated under this Agreement and to grant the licenses contained in this Agreement. 
 (b)      It is not aware of any material communications alleging that it has violated or, by conducting its obligations currently proposed under this Agreement, it would violate any of the intellectual
property rights of any Third Party, and it is unaware of any 

  

 26 
 [ *
] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
material unauthorized use, infringement or misappropriation of any of its Patents, copyrights, trademarks, trade secret rights and know-how rights necessary
or useful to manufacture, use or sell the Product. 
 (c)      All of its employees, officers and
consultants have executed agreements requiring assignment to the Party of all inventions made during the course of and as a result of their association with such Party and obligating the individual to maintain as confidential the Confidential
Information of such Party. 
 (d)      It is free to enter into this Agreement and, in so doing, will
not violate any other agreement to which it is a party. It has taken all corporate action necessary to authorize the execution and delivery of this Agreement. 
 (e)      Neither it, nor any of its employees, officers, contractors or consultants who will render services relating to the Product has ever been debarred or convicted of a crime
for which an entity or person could be debarred under 21 U.S.C. Section 335a. If such debarment or conviction should occur during the term hereof, the Party whose employees, officers, contractors or consultants has been so debarred or convicted
(or is threatened with such debarment or conviction) shall promptly notify the other Party in writing and such debarment or conviction or threat thereof shall be grounds for immediate termination of this Agreement on written notice by the other
Party. 
 (f)      It has not entered into any agreement with any Third Party that is in conflict with
the rights granted to the other Party under this Agreement. 
 (g)      It will not enter into any
agreement with any Third Party during the term hereof that will conflict with the rights granted to the other Party under this Agreement. 
 (h)      Its execution and performance of this Agreement does not conflict with any agreements or arrangements to which it is a party as of the Effective Date. 
 (i)      There has been no material breach of the Prior Agreement, the Feasibility Agreement dated June 1,
2001 (“Feasibility Agreement”) by and between Sheffield Pharmaceuticals, Inc. (“Sheffield”) and Bradford Particle Design plc (to which NEKTAR UK is the successor in interest), or the License and Supply Agreement
made and entered into as of April 26, 2002 (“Sheffield Agreement”) by and between Bradford Particle Design, Ltd. (now NEKTAR UK) and Sheffield, by such Party or its predecessors in interest, that is uncured, excluding the
following matters previously discussed by the Parties, with respect to which matters neither Party makes any agreement or admission as to whether such a breach has occurred or not: the filing of patents and ownership of inventions and patents under
such agreements and payment by MAP of the [ * ] to NEKTAR UK under the Prior Agreement. 
 10.    MUTUAL INDEMNIFICATION. 
 10.1      NEKTAR UK’s Right to Indemnification. Except with respect to claims for patent infringement as discussed in Article 9, MAP will indemnify, defend and hold 

  

 27 
 [ *
] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
harmless each of NEKTAR UK and its Affiliates and their respective successors and assigns, and their respective directors, officers, employees, and agents,
from and against any and all liabilities, damages, losses, settlements, penalties, fines, costs and expenses, including without limitation reasonable attorneys’ fees regardless of outcome (any of the foregoing to be referred to herein as
“Damages”) of whatever kind or nature (but not including taxes), to the extent arising from any Third Party claim, demand, action, suit or proceeding based on (i) the processing, manufacture, use, import, export, offer for
sale, sale, commercialization (including without limitation, promotion, distribution and marketing), handling, storage, transportation or disposal of the Compound, the Particulate Formation, the Formulation, the Device or the Product, including
without limitation as a result of the administration of the Product to humans (including in the course of human clinical trials) or any recall or market withdrawal of any Device and/or the Product; (ii) the negligence or intentional misconduct
of MAP or any of its employees, agents or contractors, (iii) a material breach by MAP of any term of this Agreement, (iv) a material misrepresentation by MAP under Section 9.5, or (v) a violation of Law by MAP or any of its
sublicensees or their respective directors, officers, employees or agents or contractors, in each case except to the extent attributable to the negligence or intentional misconduct of NEKTAR UK or any of its employees, agents or subcontractors,
material breach by NEKTAR UK of any term of this Agreement or any material misrepresentation by NEKTAR UK under Section 9.5 or a violation of Law by NEKTAR UK or its directors, officers, employees or agents or subcontractors. 
 10.2      MAP’S Right to Indemnification. Except with respect to claims for patent infringement as discussed in
Article 9, NEKTAR UK will indemnify, defend and hold harmless each of MAP, its successors and assigns and their respective directors, officers, employees and agents from and against any and all Damages of whatever kind or nature, (but not including
taxes), to the extent arising from any Third Party claim, action, suit or proceeding based (i) solely on the manufacture of the Particulate Formation of Compound by NEKTAR UK or its subcontractors (but excluding any Damages attributable to the
Compound used in such Particulate Formation of Compound or to the manufacture of the Particulate Formation of Compound by NEKTAR UK subcontractors after the Effective Date), (ii) the negligence or intentional misconduct of NEKTAR UK or any of
its employees, agents or subcontractors (iii) a material breach by NEKTAR UK of any term of this Agreement, (iv) a material misrepresentation by NEKTAR UK under Section 9.5, or (v) a violation of Law by NEKTAR UK or its
directors, officers, employees or agents or subcontractors, in each case except to the extent that the claim, action or suit is attributable to the negligence or intentional misconduct of MAP or any of its agents, employees or contractors, material
breach by MAP of any term of this Agreement, a material misrepresentation by MAP under Section 9.5 or a violation of Law by MAP or any of its sublicensees or their respective directors, officers, employees or agents or contractors, and in any
case (i) through (v) excluding any such to the extent arising out of (x) any action or omission of a person at a time when he or she is no longer an employee of Nektar, (y) after the Effective Date, the MSE or its use (excluding
any breach of a representation in Section 3.2), or (z) following any transfer of the SMP Line to MAP or its designee, the SMP Line or its use. 
  

 28 
 [ *
] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 10.3    Process for Indemnification. A Party’s obligation to defend,
indemnify and hold harmless the other Party under Sections 10.1 or 10.2 shall be conditioned upon the following: 
 (a)      A Party seeking indemnification (the “Indemnified Party”) shall give prompt written notice of the claim to the other Party (the “Indemnifying Party”);

 (b)      The Indemnified Party shall permit the Indemnifying Party to control any litigation or
other proceeding relating to such claim and disposition of any such claim, including the settlement thereof, provided that (i) the Indemnifying Party shall act reasonably and in good faith with respect to all matters relating to the settlement
or disposition of any such claim as such settlement or disposition relates to the Parties being indemnified under this Section 10.3, (ii) the Indemnifying Party shall not settle or otherwise resolve any claim without prior notice to and
the written consent of the Indemnified Party if such settlement involves any remedy other than the payment of money by the Indemnifying Party, and (iii) the Indemnified Party may be represented by counsel of its own choosing at its own expense;
and 
 (c)      The Indemnified Party shall cooperate with the Indemnifying Party in its defense of any
claim for which indemnification is sought, and shall not settle or otherwise resolve any claim without prior notice to and the written consent of the Indemnifying Party. 
 10.4    Insurance. MAP and its sublicensees at their own expense, shall maintain comprehensive general liability insurance, including product liability insurance, covering claims regarding
the development, commercialization or marketing of the Product in the minimum amount of [ * ] per occurrence, and [ * ] in the aggregate, with NEKTAR UK named as an additional insured. Such policies shall include a
provision that NEKTAR UK shall be given written notice of any termination or material change of such a policy. MAP and its sublicensees shall maintain such insurance for so long as it continues to develop, commercialize, or market the Product, and
shall from time to time provide copies of certificates of such insurance to NEKTAR UK upon its request. 
 11.    CONFIDENTIALITY. 
 11.1      Confidentiality;
Exceptions. With respect to all Information or other information furnished by one Party (or its Affiliates) to the other Party (or its Affiliates) pursuant to the Nondisclosure Agreement and/or this Agreement (collectively, “Confidential
Information”), the Party receiving such Confidential Information (the “Receiving Party”) shall maintain the confidential and proprietary status of such Confidential Information, keep such Confidential Information and each
part thereof within its possession or under its control, use all reasonable efforts to prevent the disclosure of any Confidential Information to any other person (except to its Affiliates, employees, agents and contractors who have a need to know
solely for the purposes of this Agreement and who are bound by like obligations as to confidentiality), and use all reasonable efforts to ensure that such Confidential Information is used only for those purposes specifically authorized by this
Agreement. Except to the extent expressly permitted herein, neither Party shall use the other Party’s Confidential Information to apply for nor secure intellectual property rights including patents. For clarity, NEKTAR UK agrees that it will
not 

  

 29 
 [ *
] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
disclose any Confidential Information to any Affiliate of NEKTAR UK except as required for NEKTAR UK to meet its obligations under this Agreement.
Furthermore, NEKTAR UK agrees that no Affiliate of NEKTAR UK shall use the Confidential Information of MAP disclosed to it for the purposes of developing a product containing the Compound for use in the Field. 
 11.2      The mutual obligations of confidentiality in Section 11.1 and the obligations of Section 11.4 do
not apply to Information or other information to the extent it is: 
     (a)      independently developed by the Receiving Party outside the scope and not in violation of this Agreement by employees not having access to the other Party’s
Confidential Information as demonstrated by the Receiving Party’s written records; 
     (b)      in the public domain at the time of its receipt or thereafter becomes part of the public domain through no fault of the Receiving Party; 
     (c)      received without an obligation of confidentiality from a Third Party having the
right to disclose such information and who is not disclosing such information on behalf of the disclosing Party; 
     (d)      released by the disclosing Party from the restrictions of this Article 11; or 
     (e)      was in the possession of the Receiving Party prior to its disclosure by the disclosing Party hereunder, as demonstrated by the Receiving
Party’s written records. 
 If disclosure of a Party’s Confidential Information is required by law, statute, rule or court order,
the Receiving Party may disclose such Confidential Information provided that the Receiving Party shall use reasonable efforts to obtain confidential treatment of any such disclosure, consult with the other Party and permit the other Party to
participate in seeking an appropriate protective order. 
 Notwithstanding the other provisions of this Section 11.2, NEKTAR UK and MAP
may each, to the extent necessary, disclose Confidential Information of the other Party to any governmental authority, including any Regulatory Authority, in each case solely to (i) secure patent protection for an invention made as a result of
the research and development activities undertaken by the Parties during and in the course of performing their obligations or exercising their rights under this Agreement, consistent with and permitted under Article 8, or (ii) to obtain
institutional or government approval to clinically test or market the Product. In addition, notwithstanding the other provisions of this Section 11.2, NEKTAR UK and MAP may each, to the extent necessary, disclose Confidential Information of the
other Party to any subcontractor of either NEKTAR UK or MAP performing work under this Agreement (provided such subcontractor is subject to the provisions of this Article 11) solely in order to perform research and development activities or contract
manufacturing with respect to the Product. 
 11.3      Return of Confidential Information. Each Party
shall return or destroy all Confidential Information of the other Party in its possession upon termination or expiration of 

  

 30 
 [ *
] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
this Agreement, except each Party may retain one (1) copy of the other’s Confidential Information in its legal files solely to the extent necessary
to allow such Party to perform or enjoy any of its rights or obligations that expressly survive the termination or expiration of this Agreement. 
 11.4      Competitor Covenants. In addition to the provisions of Section 11.2, with respect to any subcontractors, sublicensees or Affiliates of MAP that have substantial technology, intellectual
property or active programs to develop and exploit supercritical fluid or other technologies that may reasonably be considered to be competitive with any NEKTAR UK Core Technology that MAP is exploiting or plans to exploit under the license under
Section 2.1(a), MAP shall obtain from such entities written commercially reasonable covenants (of which NEKTAR UK shall be an express intended third party beneficiary) that are reasonably calculated to prevent the intentional or accidental use
of such NEKTAR UK Core Technology being or planned to be exploited by MAP in the entities’ competitive supercritical fluid or other technologies. Within thirty (30) days of entering into any agreement with any such subcontractor or
sublicensee or first gaining any such Affiliate, MAP will so notify NEKTAR UK in writing and provide NEKTAR UK with a copy of any such agreement, provided that MAP may redact terms other than such covenants. 
 11.5      Survival. This Article 11 shall survive the termination or expiration of this Agreement for a period of
five (5) years. 
 12.    PUBLICITY. 
 12.1      Public Disclosure. The Parties agree that the initial public announcement of the execution of this
Agreement shall be in a form and content that is mutually acceptable to both Parties. The Parties contemplate that the announcement will be a press release that describes the nature and scope of this Agreement. Subject to Article 11, either Party
may publicly disclose the general nature and scope of this Agreement and the stage of development of the Product at any time during the term of this Agreement, without the consent of the other Party. All other publicity relating to this Agreement
including its terms shall be subject to the written consent of the other Party, subject to Section 11.2. 
 12.2      Statement Regarding This Agreement. Any information disclosed publicly by MAP relating to this Agreement, whether in the form of press releases, technical publications, regulatory filings,
seminar and conference speeches and posters, interviews, videos, and other public statements regarding this Agreement, will include a prominent statement that this Agreement involves development and commercialization of a product for pulmonary
delivery of the Compound using NEKTAR UK ‘s proprietary particle-formation technology and that such product has been developed pursuant to a collaboration with NEKTAR UK. Any information disclosed publicly by NEKTAR UK related to NEKTAR
UK’s proprietary particle-formation technology concerning its collaborations for the particle engineering of pharmaceutical compounds shall include a statement that MAP is a development partner of NEKTAR UK. 
  

 31 
 [ *
] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 13.    TRADEMARKS, PRODUCT TRADEMARK;
USE OF NEKTAR UK TRADEMARK. 
 13.1      The Product,
any Device, Product packaging (including, without limitation, blister packs), promotional materials, package inserts, and labeling shall bear a trademark chosen and owned by MAP. The Product packaging, may bear the trademark, trade name, brand name,
or logo of NEKTAR UK or its permitted assignee, as provided in Article 5, and therefore, NEKTAR UK grants MAP the right to use NEKTAR UK’s trademarks, trade name, brand name, or logo solely to the extent necessary for MAP to fulfill the
obligations set forth in Article 5. MAP shall not use any trademark, trade name, brand name, or logo of NEKTAR UK or its permitted assignee outside the scope of this Agreement, and shall not take any action that would adversely affect the value of
any NEKTAR UK or permitted assignee trademark. Nothing in this Section 13.1 shall be construed as a consent by MAP to any such assignment under Section 17.2. 
 14.    TERM AND TERMINATION 
 14.1      Term. The term of this Agreement commences as of the Effective Date and, unless sooner terminated as specifically provided in this Agreement, continues in effect on a country-by-country basis,
until the expiration of all royalty obligations hereunder in respect of such country. For the purposes hereof, the royalties due under this Agreement shall continue on a country-by-country basis, from the date of Commercial Launch of the Product in
such country until the longer of (i) the duration of MAP’s royalty obligation under Section 6.2(a), (ii) ten (10) years after Commercial Launch of the Product in such country, or (iii) the date upon which all of the
NEKTAR UK Know-How licensed to MAP under this Agreement becomes known to the general public (through no fault of MAP or its sublicensees). For the purposes of this Agreement, the Parties agree that the NEKTAR UK Know-How licensed to MAP under this
Agreement will be deemed to be known to the general public on a country by country basis if there is a competitor(s) of MAP making, having made, importing or selling the Product in the Field in such country in the Territory. 
 14.2      Termination by MAP. MAP may terminate this Agreement, with or without cause, effective on (6) six
months written notice at any time. During such six (6) month period, NEKTAR UK and any Third Party consultants or contractors may continue to perform under this Agreement and MAP shall be responsible for all costs incurred thereunder plus all
unavoidable costs and expenses, including necessary expenses associated with personnel and Third Party consultants or contractors, non-cancelable commitments, and cash outlays incurred by NEKTAR UK in direct relation to NEKTAR UK’s performance
of its obligations hereunder (including, without limitation, all equipment ordered therefor that is non-cancelable or nonreturnable), even if such costs and expenses are incurred after the date of termination to the extent such costs and expenses
arise out of prior commitments. NEKTAR UK will take commercially reasonable actions to mitigate such expenses under this Section 14.2. 
 14.3      Termination for Default. If either Party believes the other is in default of any of its material obligations under this Agreement, it may give notice of such default to the other Party, which
Party has one-hundred and twenty (120) days in which to remedy such default, or thirty (30) days in the case of default in payment. Such one-hundred and twenty (120)

  

 32 
 [ *
] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
day period will be extended in the case of a default not capable of being remedied in such one-hundred and twenty (120) day period so long as the
defaulting Party uses diligent efforts to remedy such default and is pursuing a course of action that, if successful, will affect such a remedy. If such alleged default is not remedied in the time period set forth above, this Agreement shall
automatically terminate and all rights and licenses granted hereunder shall cease and revert in their entirety to the licensor thereof. In the event of a dispute regarding royalties or other amounts owing hereunder, all undisputed amounts will be
paid when due and the balance, if any, will be paid promptly after settlement of the dispute. If MAP terminates this Agreement because of NEKTAR UK’s material breach, the license granted pursuant to Section 2.1(a) survives such
termination, subject to the payment of milestones under Section 6.1 above and royalties and other payments pursuant to Section 6.2 above. The License granted by MAP to NEKTAR UK under Section 2.2 shall terminate immediately. If MAP
terminates this Agreement for any reason other than NEKTAR UK’s material breach, or if NEKTAR UK terminates this Agreement because of MAP’s material breach, all license rights granted to MAP will terminate immediately, provided, however,
that subject to the royalty obligations of MAP to NEKTAR UK under this Agreement, MAP may dispose of any Product in its inventory at the time of termination or under production at the time of termination, the license granted by MAP to NEKTAR UK
under Section 2.2 will terminate immediately and MAP will provide to NEKTAR UK summaries of all pre-clinical, clinical and other data prepared or generated during the term of this Agreement except to the extent such data relates to a Device,
and NEKTAR UK may use such summaries for NEKTAR UK’s development and/or commercialization of products other than the Product. 
 14.4      Surviving Obligations. Termination of this Agreement shall not terminate MAP’S obligation to pay all milestone payments, royalties and other payments, which have accrued hereunder
(including any milestone payments then accrued because the event has occurred but not yet due and amounts specified in Section 14.2 above). The rights and obligations of the Parties under Section 2.1(b) (License to Compound-Limited
Claims), Section 2.4 (No Implied Rights or Licenses), Article 7 (Record Keeping and Audits), Article 8 (Patents), payment obligations for rights accrued as of termination date under Article 9 (Infringement by Third Parties), Article 10 (Mutual
Indemnification), Article 11 (Confidentiality), Article 12 (Publicity), provisions of Article 14 (Term and Termination) stated therein to survive, Article 15 (Limitation of Liability and Exclusion of Damages; Disclaimer of Warranty), (Article 16
(Dispute Resolution) , Section 17.5 (Notices), Section 17.7 (Waiver), Section 17.9 (Descriptive Headings), Section 17.10 (Governing Law), Section 17.11 (Severability), and Section 17.13 (Releases) shall survive the
termination or expiration of this Agreement. 
 14.5      Challenge. NEKTAR UK shall have the right to
terminate this Agreement immediately upon written notice if MAP challenges the validity, scope or enforceability of or otherwise opposes any Patent included in the NEKTAR UK Patent Rights. If a sublicensee of MAP challenges the validity, scope or
enforceability of or otherwise opposes any Patent included in the NEKTAR Patent Rights to which such sublicensee is sublicensed, then MAP, upon written notice by NEKTAR UK, shall terminate such sublicense. MAP shall include provisions in all
agreements that grant sublicense rights under any Patent included in the NEKTAR UK Patent Rights that if the sublicensee challenges the validity or enforceability of or otherwise oppose any such Patent under which the sublicensee is sublicensed, MAP
may terminate its sublicense agreement with such sublicensee. 
  

 33 
 [ *
] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 14.6      Accrued Rights, Surviving Obligations. Such termination,
relinquishment or expiration shall not relieve either Party from obligations that are expressly indicated to survive termination or expiration of the Agreement. Termination by a Party shall not be an exclusive remedy and all other remedies will be
available to the terminating Party, in equity and at law. 
 15.    LIMITATION OF LIABILITY AND EXCLUSION OF DAMAGES;
DISCLAIMER OF WARRANTY 
 15.1      EXCEPT IN THE CASES OF OFFSETS PURSUANT TO SECTION 9.1 AGAINST
ROYALTIES PAYABLE TO NEKTAR UK AND OF NEKTAR UK’S INDEMNIFICATION OBLIGATIONS UNDER SECTION 10.2, IN NO EVENT SHALL NEKTAR UK’S LIABILITY ARISING OUT OF THIS AGREEMENT EXCEED THE AMOUNTS NEKTAR UK IS PAID BY MAP PURSUANT TO THIS AGREEMENT.

 15.2      EXCEPT IN THE CASE OF A BREACH OF ARTICLE 11, AND WITHOUT LIMITING THE PARTIES’
OBLIGATIONS UNDER ARTICLES 9 AND 10, NEITHER PARTY SHALL BE LIABLE TO THE OTHER PARTY FOR SPECIAL, INDIRECT, INCIDENTAL, PUNITIVE OR CONSEQUENTIAL DAMAGES (INCLUDING WITHOUT LIMITATION, DAMAGES RESULTING FROM LOSS OF USE, LOSS OF PROFITS,
INTERRUPTION OR LOSS OF BUSINESS OR OTHER ECONOMIC LOSS) ARISING OUT OF THIS AGREEMENT OR WITH RESPECT TO A PARTY’S PERFORMANCE OR NON-PERFORMANCE HEREUNDER. 
 15.3      The limitation on liability and exclusion of damages provided for in Sections 15.1 and 15.2 (a) apply even if a Party had or should have had knowledge, actual or
constructive, of the possibility of such damages; (b) are a fundamental element of the basis of the bargain between the Parties and this Agreement would not be entered into without such limitations and exclusions and (c) shall apply
whether a claim is based on breach of contract, breach of warranty, tort (including negligence), product liability, strict liability or otherwise, and notwithstanding any failure of essential purpose of any limited remedy herein. 
 15.4      Except as provided in Section 9.5, NEKTAR UK PROVIDES NO WARRANTIES, EXPRESS OR IMPLIED, REGARDING
THE PARTICULATE FORMATION OF COMPOUND OR NEKTAR UK PATENT RIGHTS, AND HEREBY DISCLAIMS ALL OTHER WARRANTIES, EXPRESS AND IMPLIED, INCLUDING WITHOUT LIMITATION THE IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE AND FREEDOM
FROM INFRINGEMENT OF THIRD PARTY RIGHTS. 
 16.    DISPUTE RESOLUTION

 16.1      Arbitration. Except for disputes, controversies or claims relating to intellectual property
rights (including without limitation Patent validity and enforceability and Patent claim construction) or the scope of the license granted hereunder, any dispute, controversy or claim arising under, out of or in connection with this Agreement,
including any subsequent 

  

 34 
 [ *
] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
amendments, or the validity, enforceability, construction, performance or breach thereof, shall be finally settled under the Commercial Arbitration Rules
(“Rules”) of the American Arbitration Association (“AAA”) then in force on the date of commencement of the arbitration by three (3) arbitrators appointed in accordance with those Rules, provided that the
arbitrators appointed have both (i) at least ten (10) years senior management arbitration experience at one or more pharmaceutical companies and (ii) significant arbitration experience in the pharmaceutical sector; provided,
however, if the Parties mutually agree, such arbitration may be conducted by a single mutually agreeable arbitrator. Such arbitration shall be conducted in one of the California counties of San Francisco, San Mateo or Santa Clara unless the
Parties agree otherwise. The existence of the arbitration and all proceedings and evidence therein shall be Confidential Information of the Parties. The award rendered shall be final and binding on the Parties. Judgment upon the award may be entered
in any court having jurisdiction. The Parties agree that they will not request, and the arbitrators shall have no authority to award, punitive or exemplary damages against either Party. The arbitrators must assess the costs of the arbitration,
including administrative fees and fees of the arbitrators, and the prevailing Party’s reasonable attorneys’ and experts’ fees against the Party that does not prevail in the arbitration, which the arbitrators must determine.

 16.2      Pre-Arbitration Dispute Resolution. No dispute under this Agreement shall be referred to
arbitration under Section 16.1 until the following procedures in this Section 16.2 have been satisfied. A senior vice president or more senior executive officer from each of NEKTAR UK and MAP shall meet as soon as practicable, and as
reasonably requested by either Party, to review any dispute with respect to the interpretation of any provision of this Agreement or with respect to the performance of either Party under this Agreement. If the dispute is not resolved by the chief
executive officers by written mutual agreement within thirty (30) calendar days after meeting to discuss the dispute, either Party may at any time thereafter provide the other Party written notice specifying the terms of such dispute in
reasonable detail and notifying the other Party of its decision to institute arbitration proceedings under Section 16.1. Such arbitration shall be initiated within thirty (30) calendar days of either Party providing written notice to the
other Party of its intent to institute arbitration proceedings, unless mutually agreed by the Parties to extend such time. 
 16.3      Provisional Remedy. Nothing in this Agreement shall limit the right of either Party to seek to obtain in any court of competent jurisdiction any equitable or interim relief or provisional
remedy, including injunctive relief. Seeking or obtaining such equitable or interim relief or provisional remedy in a court shall not be deemed a waiver of this Agreement to arbitrate. For clarity, any such equitable remedies shall be cumulative and
not exclusive and are in addition to any other remedies that either Party may have under this Agreement or applicable law. 
 16.4      Disputes Related to Intellectual Property Rights and License Grants. Any and all disputes, controversies or claims relating to intellectual property rights (including without limitation Patent
validity and enforceability and Patent claim construction) or the scope of the licenses granted hereunder shall be subject to the exclusive venue and jurisdiction of the federal courts of competent jurisdiction. The Parties hereby consent to the
exclusive venue and jurisdiction of such courts for such disputes, controversies or claims. 
  

 35 
 [ *
] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 17.    MISCELLANEOUS. 
 17.1      Agency. Neither Party is, nor shall be deemed to be, an employee, agent, co-venturer or legal
representative of the other Party for any purpose. Neither Party will be entitled to enter into any contracts in the name of, or on behalf of the other Party, nor will either Party be entitled to pledge the credit of the other Party in any way or
hold itself out as having the authority to do so. 
 17.2      Assignment. Except as otherwise provided
in this Section 17.2, neither this Agreement nor any interest hereunder is assignable by any Party without the prior written consent of the other (which consent will not be unreasonably withheld following the conclusion of a party’s
obligations under this Agreement); provided, however, that either Party may assign this Agreement (a) in whole or in part to any Affiliate or (b) in its entirety to any successor in interest by merger, stock transfer, or sale
of substantially all of its business (meaning in the case of NEKTAR UK, the successor or owner of the NEKTAR UK Patent Rights and the NEKTAR UK Know-How) to which this Agreement relates (provided, however, that under no circumstances
shall NEKTAR UK be permitted under this clause 17.2(b) to assign this Agreement to a Third Party that markets a product for treatment of migraine headaches or that then has a product candidate for treatment of migraine in Phase II or later phase
clinical trials, in each case (a) and (b) in a manner such that the assignor will remain liable and responsible for the performance and observance of all its duties and obligations under this Agreement. This Agreement is binding upon the
successors and permitted assignees of the Parties and the name of a Party appearing herein is deemed to include the names of such Party’s successor’s and permitted assigns to the extent necessary to carry out the intent of this Agreement.
Any assignment not in accordance with this Section 17.2 is void. 
 17.3      Further Actions. Each
Party agrees to execute, acknowledge and deliver such further instruments, and to do all such other acts, as may be necessary or appropriate in order to carry out the purposes and intent of this Agreement. 
 17.4      Force Majeure. Neither Party is liable to the other Party for loss or damages or, except as otherwise set
forth in Article 14, has any right to terminate this Agreement for any default or delay attributable to any event beyond its reasonable control and without its fault or negligence (a “Force Majeure Event”), including but not limited
to acts of God, acts of government (including injunctions), fire, flood, earthquake, strike, labor dispute, and the like. The Party affected will give prompt notice of any such cause to the other Party. The Party giving such notice shall thereupon
be excused from such of its obligations hereunder as it is thereby disabled from performing for so long as it is so disabled and for [ * ] thereafter and the Party receiving notice shall be similarly excused from its respective
obligations which it is thereby disabled from performing; provided, however, that such affected Party commences and continues to take reasonable and diligent actions to cure such cause. If the Parties are unable to resolve a default or delay in
performance of a Party’s duties under this Agreement due to an event under this Section 17.4 within [ * ] of notifying the other Party, then the Party will exert commercially reasonable efforts to find a Third Party to
supply to the other Party the product or services, which are the subject of the default, at commercially reasonable prices/costs. Notwithstanding the 

  

 36 
 [ *
] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
foregoing, nothing in this Section 17.4 will excuse or suspend the obligation to make any payment due hereunder in the manner and at the time provided.

 17.5      Notices. All notices and other communications hereunder shall be in writing and is deemed
given if delivered personally or by facsimile transmission (receipt verified), telexed, mailed by registered or certified mail (return receipt requested), postage prepaid, or sent by express courier service, to the Parties at the following addresses
(or at such other address for a Party as shall be specified by like notice; provided, that notices of a change of address is effective only upon receipt thereof): 
  

			
	If to MAP, addressed to:	  	If to NEKTAR UK, addressed to:
		
	 MAP Pharmaceuticals, Inc.
 2400 Bayshore Parkway, Suite
200
 Mountain View, CA 94043
 Attention: President and
CEO
 Facsimile: [ * ] 
	  	 NEKTAR THERAPEUTICS UK LIMITED 150 Industrial Road
 San
Carlos, CA 94070
 Attention: [ * ] 
 Facsimile:
[ * ] 

		
		  	With copy to:
		
		  	 Nektar Therapeutics
 150 Industrial Way
 San Carlos, CA 94070
 Attention: [ * ]
 Facsimile: [ * ] 

 17.6      Amendment. No amendment, modification or supplement
of any provision of this Agreement shall be valid or effective unless made in writing and signed by a duly authorized officer of each Party. 
 17.7      Waiver. No provision of this Agreement is waived by any act, omission or knowledge of a Party or its agents or employees except by an instrument in writing expressly waiving such provision and
signed by a duly authorized officer of the waiving Party. 
 17.8      Counterparts. This Agreement may
be executed simultaneously in two counterparts, either one of which need not contain the signature of more than one Party but both such counterparts taken together will constitute one and the same agreement. 
 17.9      Descriptive Headings. The descriptive headings of this Agreement are for convenience only, and have no
force or effect in construing or interpreting any of the provisions of this Agreement. 
 17.10    Governing Law.
This Agreement is governed by and interpreted in accordance with the substantive laws of the State of California, USA without regard to its or any other jurisdiction’s choice of law rules. 
  

 37 
 [ *
] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 17.11    Severability. Whenever possible, each provision of this Agreement is
interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Agreement is held to be prohibited by or invalid under applicable law, such provision shall be ineffective only to the extent of such
prohibition or invalidity, without invalidating the remainder of this Agreement. In the event of such invalidity, the Parties will seek to agree on an alternative enforceable provision that preserves the original purpose of this Agreement.

 17.12    Compliance with Law. Nothing in this Agreement is deemed to permit MAP to export, re-export or
otherwise transfer any Information transferred hereunder or the Product manufactured therefrom without complying with applicable laws. 
 17.13    Releases. As additional consideration for the Parties, each Party, subject to Sections 10.1 and 10.2 of this Agreement, hereby forever and completely releases and discharges the other Party, the other
Party’s Affiliates, and their respective officers, directors, current and former employees, agents, predecessors, successors in interest and assigns, of and from any and all claims and demands of every kind and nature, in law, equity or
otherwise, known or unknown, disclosed and/or undisclosed, existing as of the Effective Date, and arising out of or related to the Prior Agreement, the Feasibility Agreement, or the Sheffield Agreement, and any other agreement between or among
NEKTAR UK, MAP and Sheffield or, as determined as of the Effective Date, their predecessors or successors, or to the Product, the Formulation, the Particulate Formation of Compound (including the supply thereof or inventions as to the composition of
matter of, methods of making, or methods of using it), the Compound, the NEKTAR UK Patent Rights, the NEKTAR UK Know-How, excluding any such claims for a breach of the Prior Agreement, the Sheffield Agreement or the Feasibility Agreement, of which
claims such Party actually is and reasonably should be unaware as of the Effective Date and which claims are the basis for a breach of the other Party’s representation pursuant to Section 9.5(i). Each Party agrees that it is aware of and
has been fully advised by its attorney of the contents of section 1542 of the Civil Code of the State of California and any other similar provision under the laws of any other jurisdiction, and these provisions and the benefits thereof are hereby
expressly waived. Such section 1542 reads as follows: 
 Section 1542. (General Release Claims Extinguished.) A general release does not
extend to claims which the creditor does not know or suspect to exist in his favor at the time of executing the release, which if known by him must have materially affected his settlement with the debtor. 
 17.14    Entire Agreement of the Parties. This Agreement and the Exhibit attached hereto, constitute and contain the complete,
final and exclusive understanding and agreement of the Parties hereto, and cancel and supersede any and all prior negotiations, correspondence, understandings and agreements, whether oral or written, including the Non-Disclosure Agreement, between
the Parties respecting the subject matter hereof, and neither Party is liable or bound to any other Party in any manner by any representations, warranties, covenants, or agreements except as specifically set forth herein or therein. Nothing in this
Agreement, express or implied, is intended to confer upon any Party, other than the Parties hereto and their respective successors and assigns, any rights, remedies, obligations, or liabilities under or by reason of this Agreement, except as
expressly provided herein. 
  

 38 
 [ *
] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 IN WITNESS WHEREOF, the Parties hereto
have as of the Effective Date duly executed this Agreement. 
  

									
	MAP PHARMACEUTICALS, INC.	 		 	NEKTAR THERAPEUTICS UK LIMITED
					
	By:	 	 /s/ Timothy S. Nelson
	 		 	By:	 	 /s/ David Johnson

					
	Name:	 	 Timothy S. Nelson
	 		 	Name:	 	 David Johnson

					
	Title:	 	 President and CEO
	 		 	Title:	 	 Sr. VP R+D

  

 39 
 [ *
] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 EXHIBIT 1.4 
 NEKTAR UK PATENT RIGHTS 
  

	
	 Nektar UK

	       [ * ]

  

 40 
 [ *
] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 EXHIBIT 3.3(A) 
 Documents and Information Specified in Section 3.3(a) 
  

	(1)	All documents necessary to support: [ * ]. 

  

	(2)	All documents material to documenting [ * ]. 

  

	(3)	Documents detailing [ * ]. 

  

	(4)	Documents specifically relating to the [ * ]. 

  

	(5)	A full electronic version of [ * ]. 

  

	(6)	A full electronic version of [ * ]. 

  

	(7)	All documentation and other information documenting [ * ]. 

  

	(8)	All [ * ]. 

  

	(9)	Copies of all [ * ]. 

  

	(10)	Copies of any and all [ * ]. 

  

	(11)	Copies of all [ * ]. 

  

 41 
 [ *
] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.Manufacturing and Supply Agreement between Xemplar Pharmaceuticals, LLC

 EXHIBIT 10.28 
 [ * ] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
 MANUFACTURING AND SUPPLY AGREEMENT 
 THIS MANUFACTURING AND SUPPLY AGREEMENT (the “Agreement”) is made and entered into as of the 26th day of April, 2006 (the
“Effective Date”) by and between Xemplar Pharmaceuticals, LLC (“XEMPLAR”), and MAP PHARMACEUTICALS, INC., a Delaware corporation (“MAP”). XEMPLAR and MAP are sometimes referred to herein individually as a
“Party” and collectively as the “Parties.” 
 RECITALS 
 WHEREAS, MAP is engaged in the research and development of proprietary delivery systems, including its proprietary
TempoTM device, and formulations suitable for use with such delivery systems for administering drugs by inhalation; 
 WHEREAS, XEMPLAR is a contract services company focusing on the development of inhalation products and has a facility that, with some modifications, is suitable for the commercial production of
pressurized metered dose aerosol canisters for use in such proprietary delivery systems of MAP, including the TempoTM device; 
 WHEREAS, MAP desires to purchase, and XEMPLAR is willing to manufacture and supply, MAP’s clinical and commercial requirements of Product in accordance with the terms of this Agreement. 

AGREEMENT 
 NOW,
THEREFORE, in consideration of the foregoing and the covenants and promises contained in this Agreement, and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the
Parties agree as follows: 
 1.      DEFINITIONS. As used herein, the following terms
shall have the following meanings: 
 “Active Agent” means a component(s) in any particular formulation that provides the
formulation with its effectiveness, as opposed to the inactive ingredients, propellant(s), excipient(s) and carrier(s), present in the formulation; the Parties agree that the initial Active Agent shall be dihydroergotamine [ * ] and
that additional Active Agents for use with additional Products may be specified from time to time by the mutual written agreement of the parties by incorporation of an Appendix setting forth the specifications for such additional Product.

 1.1      “Affiliate” means a corporation, partnership, trust or other entity that directly,
or indirectly through one or more intermediates, controls, is controlled by or is under common control with a Party to this Agreement. For such purposes, “control,” “controlled by” and “under common control with” shall
mean the possession of the power to direct or cause the direction of the management and policies of an entity, whether through the ownership of voting stock or partnership interest, by contract or otherwise. In the case of a corporation, the direct
or indirect ownership of more than fifty percent (50%) of its outstanding voting shares or the ability otherwise to elect a majority of the board of directors or other managing authority of the entity shall in any event be deemed to confer
control, it being understood that the direct or indirect 

 
ownership of a lesser percentage of such shares shall not necessarily preclude the existence of control. 
 1.2      “Applicable Laws” means any then current local, state or federal rule, regulation, statute or law
in any jurisdiction relevant to the activities undertaken pursuant to this Agreement or applicable to either of the Parties with respect to any matters set forth herein, including, but not limited to, the rules, requirements and regulations of any
Regulatory Authority. 
 1.3      “Certificate of Analysis” means a document containing the
information contemplated by the Quality Agreement and certifying that the Product meets the terms set forth in the Quality Agreement, the Product Specification, GMP and other Applicable Law. 
 1.4      “Certificate of Compliance” means a manufacturing compliance report containing the information
contemplated by the Quality Agreement and indicating that the XEMPLAR facility is in compliance with all specifications necessary to produce the Product in compliance with the Quality Agreement, the Product Specification, GMP and other Applicable
Laws. 
 1.5      “Confidential Information” means formulas, practices, procedures, processes,
methods, knowledge, know-how, trade secrets, skill, experience, documents, apparatus, results, clinical and regulatory strategies, test data, including pharmacological, toxicological and clinical test data, analytical and quality control data,
manufacturing data and descriptions, patent and legal data, market data, financial data or descriptions, devices, assays, chemical formulations, specifications, compositions of matter, product samples and other samples, physical, chemical and
biological materials and compounds, and the like, whether or not patentable; provided, however, that Confidential Information shall not include any of the foregoing to the extent it is: 
 (a)      independently developed by the receiving Party outside the scope and not in violation of this Agreement by
employees not having access to the other Party’s Confidential Information as demonstrated by the receiving Party’s written records; 
 (b)      in the public domain at the time of its receipt or thereafter becomes part of the public domain through no fault of the receiving Party; 
 (c)      received without an obligation of confidentiality from a third party having the right to disclose such
information and who is not disclosing such information on behalf of the disclosing Party; 
 (d)      expressly designated as not being Confidential Information by the disclosing Party; or 
 (e)      was in the possession of the receiving Party prior to its disclosure by the disclosing Party hereunder, as demonstrated by the receiving Party’s written records. 
  

 2 
 [ *
] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 1.6      “Dedicated Equipment” means the items of
equipment listed in Exhibit G, as amended from time to time by the written agreement of the Parties, and required for the Facility Conversion that are dedicated exclusively to the manufacture of the Product. 
 1.7      “Effective Date” means the date set forth in the introduction to this Agreement. 
 1.8      “EMEA” means the European Medicines Evaluation Agency, or any successor thereto, which
coordinates the scientific review of human pharmaceutical products under the centralized licensing procedure in the European Union. 
 1.9      “Facility” has the meaning set forth in Section 2.1 (Facility Build-Out). 
 1.10      “Facility Approval” means any approval, permit or certification of a Regulatory Authority required to manufacture Product in the Facility in accordance with the terms of this
Agreement and Applicable Law. 
 1.11      “Facility Completion Target Date” means the date
agreed by the Parties to be inserted into Exhibit B of this Agreement, such date to be the date that XEMPLAR obtains the required approvals, including but not limited to, any Facility Approval, required to manufacture the Product in compliance with
the Quality Agreement, the Product Specifications, GMP and other Applicable Laws. 
 1.12      “Facility Conversion” means the acquisition of “Dedicated Equipment” and the conversion of the Facility into a facility equipped to manufacture the Product in accordance
with GMP and the terms and condition of this Agreement. 
 1.13      “Facility Loan” has the
meaning set forth in Section 2.2 (MAP Loan). 
 1.14      “FDA” means the United States
Food and Drug Administration, or any successor thereto, having the administrative authority to regulate the marketing of human pharmaceutical products or biological therapeutic products, delivery systems and devices in the United States. 

1.15      “FFDCA” has the meaning set forth in Section 3.7 (Warranty). 
 1.16      “Firm Order” means a binding purchase order issued by MAP to XEMPLAR in accordance with
Section 3.3 (Firm Orders). 
 1.17      “Force Majeure Event” has the meaning set forth
in Section 10.4 (Force Majeure). 
 1.18      “Forecast Quantity” means, for any
particular calendar quarter, the quantity of Product (or placebos, if applicable) forecast for such quarter in the rolling forecast issued by MAP pursuant to Section 3.2 (Forecasting). 
  

 3 
 [ *
] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 1.19      “Good Manufacturing Practices” or
“GMP” means the then-current regulations set forth in 21 C.F.R. Parts 210 – 211, 820 and 21 C.F.R. Subchapter C (Drugs), Quality System Regulations and the requirements thereunder imposed by the FDA and, as applicable, the
equivalent regulations and requirements in jurisdictions outside the United States. 
 1.20      “Invoice Documentation” has the meaning set forth in Section 3.6 (Invoice and Payment). 
 1.21      “MAA” means a marketing approval application filed with the EMEA for regulatory approval to market and sell Product in the European Union and similar in
purpose to the NDA in the United States. 
 1.22      “Manufacturing Cost Per Unit” means,
with respect to Product delivered during a calendar quarter, [ * ] determined in accordance with generally accepted accounting principles and consistent with XEMPLAR’s accounting practices on its other products, consisting of
the following: 
 (a)      Materials. The cost of Specified Components which form an integral
and direct part of the Product, or are necessary for its production or distribution, but excluding those components that are supplied at MAP’s expense. 
 (b)      Direct Labor and Benefits. The cost of [ * ] for XEMPLAR employees engaged in the actual production of the Product, including
[ * ]. The costs associated with an employee that does not spend 100% of his or her time on the actual production of the Product shall be allocated to Manufacturing Cost Per Unit based on the time spent by such employee on
the actual production of the Product divided by the total working time of such employee. 
 (c)      Allocated Overhead. [ * ] allocated to the [ * ] including: (i) [ * ]; (ii) [ * ];
(iii) [ * ]; (iv) [ * ]; (v) [ * ]; (vi) [ * ]; (vii) [ * ]; (viii) [ * ]; (ix) [ * ];
(x) [ * ]; (xi) [ * ]; (xii) [ * ]; (xiii) [ * ]. 
 1.23      “MAP Technology” means products, processes, methods, inventions, patents, technologies, Confidential Information, and other proprietary rights owned, licensed or otherwise controlled
by MAP. 
 1.24      “NDA” means (a) the single application or set of applications to
make and sell commercially the Product filed with the FDA or any successor agency having the administrative authority to regulate the approval for marketing of new human pharmaceuticals or biological therapeutic products, delivery systems and
devices in the United States and (b) any related registrations with or notifications to the FDA. 
 1.25      “Product” means placebos containing only propellant for use in clinical trials or commercial trainer or samples, as well as the product containing Active Ingredient along with its
excipient(s) and propellant(s), all of the preceding packaged in canisters and housed 

  

 4 
 [ *
] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
within a fully assembled TempoTM device and all packaging required release and distribution for clinical supplies and for commercial sale... 
 1.26      “Product Specifications” means the specifications set forth on Exhibit A hereto. 
 1.27      “Quality Agreement” means the Quality Agreement entered into between MAP and XEMPLAR, stipulating specific requirements, obligations and embodiments of the
quality systems implementation, maintenance and operation. 
 1.28      “Regulatory Approval”
means (a) in the United States, approval by the FDA of an NDA or other applicable filing and satisfaction of any related applicable FDA registration and notification requirements (if any) and (b) in any country or jurisdiction other
than the United States, e.g., European Union, approval by regulatory authorities having jurisdiction over such country or jurisdiction, e.g., EMEA, of a single application or set of applications comparable to an NDA or other applicable filing, e.g.,
MAA, and satisfaction of any related applicable regulatory and notification requirements, if any, together with any other approval necessary to make and sell pharmaceuticals commercially in such country jurisdiction. 
 1.29      “Regulatory Authority” means the FDA or any successor agency in the United States, and the
equivalent regulatory authorities in other jurisdictions, e.g., EMEA. 
 1.30      “Restricted
Products” means a Product(s) for use in [ * ]. 
 1.31      “Specified Components” means the TempoTM device
components, canisters, valves, propellant and the Active Agent, excipients, cartons, labels, package inserts and shippers. 
 1.32      “Staffing Loan” has the meaning set forth in Section 2.2 (MAP Loan). 
 1.33      “Testing Laboratory” has the meaning set forth in Section 3.8 (Failure or Inability to Supply Conforming Product). 
 1.34      “Testing Methods” has the meaning set forth in Section 5.1 (Testing Requirements).

 1.35      “Unit of Product” means an individual unit of the Product. 
 2.      FACILITY BUILD-OUT AND LOAN

 2.1      Facility Build-Out. 
 (a)      XEMPLAR will convert its manufacturing facility located at 927 Currant Road in Fall River, Massachusetts
(the “Facility”) into a GMP contract manufacturing facility satisfactory for the commercial production of Product in accordance with the terms of this Agreement, GMP and other Applicable Law on or before the Facility Completion
Target 

  

 5 
 [ *
] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
Date in accordance with the purposed and phasing timeline set forth in Exhibit B and the costs and timeline set forth in Exhibit C hereto. 

(b)      XEMPLAR shall not purchase any equipment, related to MAP Product, for the Facility, without the prior
written approval of MAP. Any used equipment purchased for the Facility for use in manufacturing MAP Product must be discussed with MAP and agreed to by MAP prior to purchase 
 (c)      XEMPLAR shall hire personnel to complete the Facility Conversion in accordance with the facility staffing
plan attached hereto as Exhibit D. 
 2.2      MAP Loan. 
 (a)      MAP shall provide to XEMPLAR (i) up to [ * ] including the [ * ]
(the “Facility Loan”) and (ii) up to [ * ] for staffing the facility during the Facility Conversion (the “Staffing Loan”), all in accordance with the terms of this Agreement.
[ * ] shall [ * ], unless otherwise required by an Applicable Law. 
 (b)      XEMPLAR shall use the proceeds of the Facility Loan only for the Facility Conversion in accordance with Exhibit B hereto. MAP shall advance the proceeds of the Facility to XEMPLAR
[ * ], subject to [ * ] set forth on Exhibit C; provided, however, that in no event shall XEMPLAR use the proceeds of the Facility Loan to cover [ * ]. 
 (c)      XEMPLAR intends to use the proceeds of the Staffing Loan for the purpose of paying wages and benefits of
XEMPLAR employees dedicated to the Facility Conversion so long as such employees are, in fact, dedicated to the Facility Conversion (the “Dedicated Employees”) in accordance with the facility staffing plan attached hereto as
Exhibit D. MAP shall advance the proceeds of the Staffing Loan to XEMPLAR from month to month beginning on the date of [ * ] upon written request of XEMPLAR; provided, however, that in no event shall XEMPLAR draw
[ * ] more than the amount necessary to fund [ * ]. Unused proceeds may be [ * ]. 
 (d)      XEMPLAR shall repay the combined principal of the Facility Loan and the Staffing Loan in [ * ] commencing on [ * ] and on [ * ] through and
including [ * ]; provided, however, that if MAP fails to [ * ], XEMPLAR’s repayment obligation shall be suspended during such [ * ]. XEMPLAR’s repayment obligations shall resume during
[ * ] of the [ * ] during which deliveries of Product are scheduled, and the repayment period shall be extended accordingly. In the event that XEMPLAR submits a repayment of the combined principal of the Facility
Loan or the Staffing Loan [ * ], such repayment shall [ * ]. 
 2.3      Dedicated Equipment. MAP shall purchase, asset tag and own the Dedicated Equipment used in the Facility and the cost of such Dedicated Equipment shall be deducted from the Facility Loan
amount and resulting Facility Loan repayments. Any damage or wear to the Dedicated Equipment which necessitates repair or replacement will be the 

  

 6 
 [ *
] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
responsibility of MAP unless such damage or wear is caused by improper use by XEMPLAR, in which case the responsibility for repair or replacement shall be
the responsibility of XEMPLAR. 
 2.4      [ * ] Exclusivity. XEMPLAR agrees not to
manufacture commercially in the [ * ], using [ * ] for any company but MAP. 
 2.5      Additional Product Manufacturing Option. As partial consideration for the refundable loan provided by MAP, MAP shall have a first option to manufacture pulmonary delivery products for
[ * ] with Xemplar under the same terms as this agreement. Should Xemplar be approached by a third party to manufacture a pulmonary delivery product for [ * ] (as defined by a term sheet agreed in writing by both
parties), then Xemplar shall provide MAP with a first option to enter into a manufacturing agreement with Xemplar for such product class under this agreement. If MAP does not elect to exercise such option within [ * ], then Xemplar
shall be free to enter into an agreement with such third party. 
 3.      SUPPLY
OF PRODUCT. 
 3.1      Purchase Commitment. During the period
beginning on the date the first NDA is submitted for a Product and for a period of five (5) years thereafter (the “Exclusivity Period”), subject to and in accordance with the terms and conditions of this Agreement, MAP shall
purchase from XEMPLAR, and XEMPLAR shall manufacture and supply to MAP from Xemplar’s Fall River, Massachussetts manufacturing facility (a) all Product required by MAP in support of development and registration lots for the clinical trials
and (b) all of the MAP’s commercial requirements of the Product. MAP shall have the right to qualify a second source of supply for Product and to obtain Product from that second source of supply. 
 3.2      Forecasting. Attached hereto as Exhibit E is an estimated rolling forecast of MAP’s
requirements for the Product (and placebos, if any) during the next eight (8) calendar quarters and the subsequent three (3) years (the “Forecast Quantity”). On or before the thirtieth (30th) day of each calendar quarter
during the term of this Agreement, commencing with the third quarter of 2006, MAP shall submit an updated Forecast Quantity for the succeeding eight (8) calendar quarters and the subsequent three years. MAP shall purchase not less than
[ * ]. XEMPLAR shall not be required to supply more than [ * ] of the rolling forecast; provided, however, that anything in this Agreement to the contrary notwithstanding, MAP shall not be required to purchase any
quantity of Product beyond that required for clinical trials until and unless MAP obtains Regulatory Approval for the Product. Except as otherwise provided in this Section, the Forecast Quantity shall be non-binding and shall be used by XEMPLAR for
planning purposes only. The Parties agree that the Forecast Quantity may be amended from time to time by the Parties by a joint written agreement. 
 3.3      Firm Orders. Not later than thirty (30) days prior to commencement of the third calendar quarter of 2006 and each calendar quarter thereafter, MAP shall submit to XEMPLAR a Firm
Order for the quantity of the Product, if any, (and placebos, if any) that MAP desires to purchase from XEMPLAR during such calendar quarter, with a statement of the dates on which delivery shall be required and shipping instructions therefore;
provided that, each Firm 

  

 7 
 [ *
] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
Order shall specify a quantity of Product , if any, MAP (and placebos, if any) not less than [ * ] as set forth in Section 3.2 unless
XEMPLAR consents in writing to a lesser quantity. If the Firm Order specifies a quantity greater than [ * ], then XEMPLAR shall not be required to supply Product in excess of such amount, but shall use commercially reasonably
efforts to do so. In the event XEMPLAR notifies MAP that it cannot meet the quantity of Product specified by MAP during the first four (4) quarters of the Forecast Quantity or if XEMPLAR is unable or unwilling to supply quantities of Product
greater than [ * ], MAP shall have the right to purchase such additional quantities of Product for a third party or manufacture such additional quantities of Product itself. Prior to the third calendar quarter of 2006 XEMPLAR shall
use commercially reasonable efforts to supply MAP with the quantities of Product (and placebos, if any) reasonably requested by MAP. 
 3.4      Delivery. MAP shall arrange for shipment of the Product ordered by MAP as per the terms of this Agreement via common carrier of MAP’s choice to the place of delivery specified by MAP
in the applicable Firm Order. MAP shall pay all shipping, insurance, duties and other governmental charges relating to the delivery of the Product. Risk of loss of a shipment shall not pass to MAP until the Product leaves XEMPLAR’s facility.

 3.5      Price; Specified Components. 
 (a)      The price per Unit of Product for clinical supplies and pre-commercial samples of the Product (and
placebos, if any) shall be equal to the lesser of (i) the [ * ] or (ii) [ * ] or [ * ]. 
 (b)      The price per Unit of Product for commercial supplies of the Product shall be equal to the lesser of (i) [ * ] or
(ii) (A) [ * ] , (B) [ * ] , or (C) [ * ]. For the sake of clarity, the pricing for the [ * ] specified in subsection (ii) above shall apply to all Units
ordered by MAP for delivery under said [ * ] during such calendar quarter. For example, if MAP orders for scheduled delivery [ * ] during a given calendar quarter, the price for each Unit of Product shall be not
more than [ * ] and the total amount paid to XEMPLAR by MAP shall be not more than [ * ]. For the purpose of this Section 3.5(b), commercial supplies shall mean all Units to be ordered for scheduled delivery by
MAP for shipment to the trade channels or a sublicensee after MAP receives a Regulatory Approval in the United States or in another region. 
 (c)      MAP shall provide the Specified Components to XEMPLAR for use in manufacturing all Product at MAP’s expense. MAP shall arrange for shipment of the Specified Components to XEMPLAR as per the
terms of this Agreement via common carrier of MAP’S choice to the Facility. MAP shall pay all shipping, insurance, duties and other governmental charges relating to the delivery of the Specified Components to XEMPLAR. Risk of loss of a shipment
shall not pass to XEMPLAR until delivery of the Specified Components to the Facility. Once the specified components are delivered to the facility, the risk of loss of such Specified Components shall transfer to XEMPLAR, provided however, that the
title to such Specified Components shall remain with MAP. The costs of such Specified Components shall [ * ] as set forth in Sections 3.5(a) and 3.5(b). XEMPLAR will retain exclusive control over all Specified Components supplied to
it by MAP hereunder, and will not transfer any portion of the 

  

 8 
 [ *
] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
Specified Components to any third party without the prior written consent of MAP. XEMPLAR shall identify the Specified Components at all times as MAP
property and segregate such Specified Components from other substances except as needed to perform its responsibilities hereunder. XEMPLAR shall not take any action inconsistent with MAP’s ownership of the Specified Components. 
 (d)      Excluding the Specified Components, XEMPLAR shall be responsible for all costs and expenses incurred in
connection with the manufacture of the Product pursuant to this Agreement, including costs and expenses of personnel and testing, including quality control and release testing, manufacturing facilities and equipment including maintenance, labeling,
packaging materials and all other supplies of any kind used in connection with manufacturing the Product if any (and placebos, if any) including manual labeling and packaging of Product, which costs shall [ * ]; provided that MAP,
in its sole discretion, but upon reasonable advance notice to XEMPLAR, may, at its cost, supply to XEMPLAR materials, including any or all of the Specified Components to be used in the manufacture of the Product, in which event the cost of such
materials shall [ * ] for the Products. Xemplar will be responsible for replacement of Specified Components for failed or recalled batches or lots for which an appropriate out of specification (OOS) investigation per the quality
agreement has concluded that Xemplar actions resulted in the failure. 
 (e)      MAP has, at its
expense (except as provided below), the right to audit, on an annual basis, XEMPLAR’s records to the extent necessary to determine the accuracy of [ * ]. If MAP desires to audit such records, it will engage an independent,
certified public accountant reasonably acceptable to XEMPLAR to examine such records. Such accountant will be instructed to provide to MAP a report on its findings, but will not disclose to MAP any confidential information of XEMPLAR not necessary
therefore. The expense of such audit will be borne by MAP; provided, however, that if an error of more than [ * ] is discovered, then such expenses shall be paid by XEMPLAR. Such auditors shall not be paid on a contingency basis.
Both parties recognize, in this regard, the differences in payments for precommercial and commercial material described in this agreement. 
 3.6      Invoice and Payment. XEMPLAR shall promptly invoice MAP for all pre-commercial and commercial supplies of the Unit of Product manufactured and delivered in accordance with the terms of
this Agreement. All invoices shall be accompanied by a Certificate of Analysis, a Certificate of Compliance and all other documentation required by the Quality Agreement (the “Invoice Documentation”). Payment for purchased Product
shall be due within thirty (30) days after the later of (a) delivery of the Product or (b) delivery of the corresponding invoice and Invoice Documentation. All shipments will be made by Xemplar [ * ] their facility to
a to facility to be determined by MAP. 
 3.7      Warranty. XEMPLAR warrants that, at the time
of delivery of the Product to MAP: (a) such Product will have been manufactured, held and shipped in accordance with the Regulatory Approvals for the Product, applicable GMP and all other Applicable Law; (b) such Product will have been
manufactured in accordance, and be in conformity, with the Product Specifications and will conform with the corresponding Invoice Documentation (c) such 

  

 9 
 [ *
] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
Product will not be adulterated or misbranded under the Federal Food, Drug, and Cosmetic Act, as amended (the “FFDCA”), and similar
provisions of the laws of other countries as to which Regulatory Approvals have been granted with respect to the Product; (d) title to such Product will pass to MAP as provided herein free and clear of any security interest, lien or other
encumbrance of XEMPLAR and its Affiliates; (e) such Product will have been manufactured at the Facility, and that the Facility shall be in material compliance with all Applicable Laws at the time of such manufacture (including applicable
inspection requirements of FDA and other Regulatory Authorities); and (f) such Product may be introduced into interstate commerce pursuant to the FFDCA and comparable rules or regulations of other Regulatory Authorities. 
 3.8      Failure or Inability to Supply Conforming Product. 
 (a)      Notification. In the event that XEMPLAR, at any time during the term of this Agreement, shall have
reason to believe that it will be unable to supply MAP with the full, conforming quantity of the Product forecasted to be ordered by MAP under a rolling forecast or actually ordered by MAP under a Firm Commitment in a timely manner, XEMPLAR shall
promptly notify MAP thereof. Promptly thereafter, the Parties shall meet to discuss how MAP shall obtain such full quantity of conforming Product. 
 (b)      Non-Conformity. In the event that MAP reasonably determines, within thirty (30) days after delivery thereof by XEMPLAR, that any Product supplied by XEMPLAR does not conform to one
or more of the warranties set forth in Section 3.7, MAP shall give XEMPLAR notice thereof, including a sample of such Product (the “Alleged Non-Conforming Product”); provided, however, that if any non-conformity is not readily
discoverable by MAP within such 30 day period, then MAP shall be entitled to deliver such notice at any time within 10 days after discovering such non-conformity. XEMPLAR shall then undertake appropriate testing of such sample of the Alleged
Non-Conforming Product and shall notify MAP whether it has confirmed such non-conformity within thirty (30) days after receipt of such notice from MAP. If XEMPLAR notifies MAP that it has not confirmed such non-conformity, the parties shall
submit a sample of the Alleged Non-Conforming Product to an independent testing laboratory mutually acceptable to the Parties (the “Testing Laboratory”) for testing. The findings of the Testing Laboratory shall be binding on the
Parties. The expenses of the Testing Laboratory shall be borne by XEMPLAR if the testing confirms the non-conformity and otherwise by MAP. If the Testing Laboratory or XEMPLAR confirms that a batch of Product does not conform to one or more of the
warranties set forth in Section 3.7, then XEMPLAR shall promptly (i) supply MAP with a conforming quantity of the Product at XEMPLAR’s sole expense, including the costs of the Specified Components or (ii) reimburse MAP for all
reasonable costs MAP may have directly incurred with respect to such non-conforming Product, including the price paid by MAP with respect to such non-conforming Product and the costs of the Specified Components incorporated into such non-conforming
Product, which costs MAP shall have the right to offset against any payments owed by MAP to XEMPLAR under this Agreement. 
 (c)      Rights and Remedies. If XEMPLAR fails [ * ] to supply the full quantity of Product specified in a Firm Order by the delivery date specified therein and in 

  

 10 
 [ *
] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
conformity with the warranty set forth in Section 3.7, MAP may, in its sole discretion, immediately terminate this Agreement by providing written notice
to XEMPLAR, and thereafter MAP may manufacture Product itself or purchase its requirements for Product from another party. If MAP terminates this Agreement under the terms of this clause, any and all outstanding principal under the Facility Loan and
the Staffing Loan shall become due and payable within ninety (90) days after termination. For clarity, nothing in this Agreement prohibits MAP from qualifying a second manufacturing source for supply of Products on a commercial scale.

 3.9      Inconsistent Terms. The terms and conditions of this Agreement shall govern all
purchase of Product by MAP from XEMPLAR during the term of this Agreement, notwithstanding that a purchase order or the standard shipping document conflict or provide for additional or different obligations than the terms and conditions of this
Agreement. Unless expressly consented to by both Parties in writing, any such additional or different terms in any such purchase order or shipping documents are hereby expressly rejected. 
 3.10      Exclusivity. During the term of this Agreement, XEMPLAR shall not manufacture any Restricted
Products for any party other than MAP. 
 4.      REGULATORY MATTERS.

 4.1      Facility Approval. XEMPLAR, at its expense, shall use all commercially reasonable efforts to
obtain any and all Facility Approvals as promptly as possible in accordance with the terms of this Agreement. 
 4.2      Product Approval. MAP, at its expense, shall use all commercially reasonable efforts to obtain Regulatory Approval for the Product in accordance with the terms of this Agreement. XEMPLAR shall
assist MAP with its application for Regulatory Approval for the Product in accordance with the terms of this Agreement. 
 4.3      Regulatory Inspections. XEMPLAR shall notify MAP by telephone within one (1) business day, and in writing within five (5) business days, after learning thereof, of any proposed or
unannounced visit or inspection of the Facility (or any other facility owned, operated or controlled by XEMPLAR or its Affiliates, at which the Product, or any part thereof, is manufactured) or of any manufacturing process used in connection with
the manufacture of the Product, by any Regulatory Authority, and shall permit MAP or its agents to be present and participate in such visit or inspection. XEMPLAR shall provide to MAP a copy of any report and other written communications received
from such Regulatory Authority in connection with such visit or inspection, and any written communications received from such Regulatory Authority relating to the Product, the Facility (or any other facility owned, operated or controlled by XEMPLAR
or its Affiliates, at which the Product, or any part thereof, is manufactured) within three (3) business days after receipt thereof, and shall consult with MAP concerning the response of XEMPLAR to each such communication. XEMPLAR shall provide
MAP with a copy of all draft responses for comment as soon as possible. XEMPLAR shall provide any proposed final response to the Regulatory Authority at least five (5) business days prior to its anticipated submission thereof to such Regulatory
Authority. XEMPLAR shall not submit any 

  

 11 
 [ *
] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
final responses to the Regulatory Authority without the approval of MAP, which approval shall not be unreasonably withheld or delayed. 
 4.4      Product Recalls. If (a) any Regulatory Authority withdraws the approval to sell the Product in a
country or issues a directive or requests that the Product be recalled from the market for safety reasons, (b) any Regulatory Authority or court of competent jurisdiction issues a request, directive or order that the Product be recalled or
(c) MAP shall reasonably determine that the Product should be recalled, then the Parties shall take all appropriate corrective actions, and shall cooperate in any investigations by a governmental authority or Regulatory Agency surrounding the
recall. In the event that such recall results from any cause or event arising from defective manufacture, storage or handling of the Product or Specified Components by XEMPLAR, then XEMPLAR shall be responsible for all expenses of the recall.
XEMPLAR shall, at MAP’s option, either refund the purchase price for recalled Product (including the price of the Specified Components) or replace recalled Product held by MAP or its customers consistent with directions received from the
appropriate governmental authority within a reasonable time at XEMPLAR sole expense, including freight and applicable duties, unless the recall is due to an act or omission of MAP or its agents. For the purposes of this Agreement, the expenses of
recall shall include, without limitation, the expenses of notification and destruction or return of the recalled Product and all other costs incurred in connection with such recall. 
 5.      TESTING, ASSAYS, STABILITY AND
QUALITY ASSURANCE. 
 5.1      Testing Requirements. XEMPLAR
shall be responsible for the performance of and compliance with all Product testing required by the Product Specifications, the Manufacturing Processes, the Applicable Laws and Regulatory Approvals for the Product. XEMPLAR shall conduct quality
control testing of Product prior to shipment, in accordance with the Product Specifications the Applicable Laws and applicable manufacturing standards as are in effect from time to time and such other quality control testing procedures requested by
MAP from time to time (collectively, the “Testing Methods”). Initially and until decided otherwise by MAP, the Testing Methods shall include all required release testing and XEMPLAR shall undertake all such tests as specified in
Exhibit F. XEMPLAR shall retain all records pertaining to such testing as required by any Applicable Law and provide copies of the same to MAP upon request. XEMPLAR agrees to implement and maintain such processing control procedures as MAP
may reasonably request or as required by any Applicable Law, including, but not limited to, the assignment of identification numbers to each lot of Product and the maintenance of production records, quality control records, batch records and related
information. XEMPLAR shall provide copies of such process control procedures and documentation produced thereunder to MAP at MAP’s request or to a Regulatory Authority if so requested by MAP. 
 5.2      Retention of Samples. XEMPLAR shall take and retain, for such period as may be required by
Applicable Law or such longer period as otherwise reasonably required by MAP, samples of Product (with appropriate quality control records regarding the manufacture and testing of such sample of Product) (i) sufficient to satisfy XEMPLAR’s
obligations under this Agreement, GMP and Applicable Law with respect to its manufacturing of the Product, (ii)

  

 12 
 [ *
] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
sufficient to perform quality control testing and stability testing in accordance with this Agreement, the Regulatory Approvals for the Product, GMP and all
other Applicable Law, and (iii) as otherwise reasonably required by MAP, and in each case shall specify the control number and the date of manufacture thereof. Further, XEMPLAR shall submit to MAP, upon MAP’s written request, such samples,
materials and quality control records as MAP may reasonably request. 
 5.3      Maintenance of
Facilities. XEMPLAR shall ensure that any and all necessary licenses, registrations, and Facility Approvals have been obtained in connection with Facility and the equipment used in connection with the manufacture of the Product by XEMPLAR.
XEMPLAR shall maintain the Facility and all equipment used in connection with this Agreement in a state of repair and operating efficiency consistent with the requirements of the Product Specifications, the Regulatory Approvals, the manufacturing
processes, GMP and all other Applicable Law. Prior to each use of any equipment in manufacturing the Product, XEMPLAR shall implement a maintenance validation protocol and a cleaning validation protocol with respect to such equipment, including the
cleaning and maintenance thereof, in accordance with any procedures reasonably established by MAP and notified to XEMPLAR, the Product Specifications, the Regulatory Approvals and the Manufacturing Processes, GMP and all other Applicable Law.
XEMPLAR shall maintain in such facilities adequate and segregated (if required) holding accommodations for the Product, the Active Agent, the excipient(s), propellant(s), packaging components, and other items used in manufacturing the Product in
accordance with the Product Specifications, the Regulatory Approvals and the Manufacturing Process, GMP and all other Applicable Law. If required under Applicable Law, all Product shall be held by XEMPLAR in a separate segregated area until delivery
to MAP. 
 5.4      Quality Control. XEMPLAR will establish a quality control unit that is physically
partitioned and operationally independent of the research and development or manufacturing operations at the Facility as required under GMP and all other Applicable Law. All quality control unit documentation, methods, procedures and validations
shall comply with the Quality Agreement, GMP and all other Applicable Law. 
 5.5      Inspection by
MAP. XEMPLAR agrees that MAP and its agents shall have the right, upon reasonable prior notice (a minimum of ten (10) working days) to XEMPLAR, to inspect the Facility (or any other facility owned, operated or controlled by XEMPLAR or its
Affiliates, at which the Product, or any part thereof, is manufactured) as well as the manufacturing of the Product, as applicable, including inspection of (a) the materials used in the manufacture of the Product, (b) the holding
facilities for such materials, (c) the equipment used in the manufacture of the Product, and (d) all records, including manufacturing and quality control records, relating to such manufacturing. MAP and/or its agents will be allowed to be
present for all MAP audits; the audits must be conducted by XEMPLAR in compliance with the Quality Agreement. Following such inspection, MAP shall discuss its observations and conclusions with XEMPLAR and corrective actions for any defects observed
by MAP shall be agreed upon by MAP and XEMPLAR within five (5) business days thereafter. XEMPLAR shall implement such corrective action within thirty (30) days after the parties reach such agreement, unless otherwise agreed in writing by
the Parties. Failure to take such corrective action as 

  

 13 
 [ *
] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
requested by MAP shall be a material breach of this Agreement and MAP shall have the rights set forth in Section 3.8(c), in addition to other as set
forth in this Agreement, Without limiting MAP’s rights under this Section, the Parties agree that quality inspections shall be conducted in accordance with the quality inspection points identified on Exhibit G hereto. 
 5.6      Manufacturing Records. XEMPLAR shall maintain, or cause to be maintained, (i) all records necessary to
comply with GMP and all other Applicable Law relating to the Manufacture of the Product including Batch Records, (ii) all Manufacturing records, standard operating procedures, equipment log books, batch records, laboratory notebooks and all raw
data relating to the Manufacturing of the Product, and (iii) such other records as MAP may reasonably require in order to ensure compliance by XEMPLAR with the terms of this Agreement. All such material shall be retained for such period as may
be required by GMP and all other Applicable Law or for such longer period as MAP may reasonably require; provided, however, that all records relating to the Manufacturing, stability and quality control of each batch of the Product
shall be retained at least until the first anniversary of the end of the approved shelf life for all Product from such batch. 
 5.7      Labeling. MAP shall specify all labeling to be used on the Product and the packaging thereof. Such labeling shall conform to the requirements of the Applicable Law as determined by MAP. XEMPLAR
agrees to use such labeling (and only such labeling) on the Product, and not to use such labeling on any other product. 
 6.       CONFIDENTIALITY; PROPRIETARY RIGHTS. 
 6.1      Publicity. The Parties shall (a) keep the material terms of this Agreement confidential; (b) agree upon the text and the exact timing of an initial public announcement relating to the
transactions contemplated by this Agreement as soon as possible after the Effective Date (such agreement not to be unreasonably withheld by either Party); and (c) agree on the text and the timing of any subsequent public announcements regarding
this Agreement or the transactions contemplated herein. Neither Party shall use the name of the other Party or any director, officer or employee of the other Party or any adaptation thereof in any advertising, promotional or sales literature or
publicity without the prior written approval of the other Party. If this Agreement is required to be filed by either Party with the Securities and Exchange Commission or another applicable securities regulatory authority, to the extent reasonable,
such Party shall request confidential treatment for any provisions of this Agreement that the other Party believes would disclose trade secrets, confidential commercial or financial information that would impair the value of the contractual rights
represented by this Agreement or provide detailed commercial and financial information to competitors or third parties. 
 6.2      Confidentiality. The requirements and obligations of this Section 6.2 hereby supercede and replace the requirements and obligations of the Confidentiality Agreement previously entered into
by and between XEMPLAR and MAP. 
 (a)      It is contemplated that in the course of the performance of
this Agreement each Party may, from time to time, disclose Confidential Information to the other. 

  

 14 
 [ *
] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
Each Party agrees that any Confidential Information disclosed by either Party in accordance with this Agreement shall be maintained in secrecy and each will
use all reasonable diligence to prevent disclosure except to such Party’s personnel and consultants where disclosure to such personnel or consultants is necessary in order to accomplish the purposes for which the Confidential Information was
disclosed to the receiving Party and provided further that such personnel and consultants are bound by confidentiality obligations covering such information at least as restrictive as this Agreement. Each Party agrees that it will protect and
maintain the confidentiality of the Confidential Information that it receives from the other with at least the same degree of care as it uses to protect its own confidential information. Each Party hereby further agrees that it will not use the
Confidential Information for any purpose other than as contemplated by this Agreement. 
 (b)      On
termination of this Agreement or at the disclosing Party’s request, all written, recorded, graphical, or other tangible embodiments of Confidential Information, including copies, shall be returned to the disclosing Party or destroyed by the
receiving Party as directed in writing by the disclosing Party; provided, however, that the receiving Party may retain one copy of such tangible embodiments of Confidential Information for the sole purpose of documenting the Confidential Information
received by the receiving Party in the event of any dispute with the disclosing Party. Such copies may not be reproduced or used for any other purpose. At the request of the disclosing Party, the receiving Party will furnish a certificate, signed by
an officer of the receiving Party, certifying that any Confidential Information not returned to the disclosing Party has been destroyed, subject only to the foregoing exception. 
 (c)      No right or license in Confidential Information is granted by this Agreement, and the disclosure of
Confidential Information does not result in any obligation to grant either Party any right in and to such Confidential Information. 
 (d)      If disclosure of a Party’s Confidential Information is required by law, statute, rule or court order, the receiving Party may disclose such Confidential Information provided that the
receiving Party shall use reasonable efforts to obtain confidential treatment of any such disclosure, consult with the other Party and permit the other Party to participate in seeking an appropriate protective order. 
 (e)      Notwithstanding the other provisions of this Agreement or any other agreement between the Parties, MAP may
disclose Confidential Information of XEMPLAR to any governmental authority, including any Regulatory Authority, to the extent necessary to apply for Regulatory Approvals and shall notify XEMPLAR of such disclosure. 
 6.3      Proprietary Rights. 
 (a)      This Agreement does not convey to XEMPLAR any rights in any MAP Technology by implication, estoppel or otherwise, except for the rights expressly granted under this
Agreement. Title to the MAP Technology and Product (and the intellectual property rights embodied in the Product) shall at all times remain vested in MAP. Any intellectual 

  

 15 
 [ *
] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
property, including but not limited to patent, trademark and copyright, developed during the term of this Agreement and for a period of one year thereafter
relating to the Product or tis manufacture and any improvements to the MAP Technology (the “Developed Intellectual Property”), whether or not patentable, shall be the sole property of MAP. XEMPLAR agrees to execute any and all
assignments or other documents useful or necessary to vest such ownership interest to the Developed Intellectual Property in MAP. 
 (b)      XEMPLAR shall not, without the prior written permission of MAP, modify, reverse engineer the MAP Technology. XEMPLAR shall use the MAP Technology and any Developed Intellectual Property solely
for fulfilling its responsibilities under this Agreement 
 7.      ADDITIONAL
REPRESENTATIONS AND WARRANTIES. 
 7.1      XEMPLAR
Representations and Warranties. XEMPLAR represents and warrants to MAP that (a) the execution, delivery and performance of this Agreement by XEMPLAR has been duly authorized and approved by all requisite limited liability company
action, (b) this Agreement constitutes the valid and binding obligation of XEMPLAR enforceable against it in accordance with its terms and (c) the execution, delivery and performance of this Agreement by XEMPLAR does not (i) violate
any law, regulation or rule of any court, governmental authority or administrative or other agency having jurisdiction over it or (ii) violate, breach or constitute a default under (with or without notice or lapse of time) XEMPLAR’s
certificate of formation or operating agreement or its obligations under any other agreement, contract, commitment or instrument by which it or any of its assets are bound or (iii) conflict with any pre-existing contract or obligation of
XEMPLAR or its Affiliates. 
 7.2      MAP Representation and Warranties. MAP represents and
warrants to XEMPLAR that (a) the execution, delivery and performance of this Agreement by MAP has been duly authorized and approved by all requisite corporate action, (b) this Agreement constitutes the valid and binding obligation of MAP
enforceable against it in accordance with its terms and (c) the execution, delivery and performance of this Agreement by MAP does not (i) violate any law, regulation or rule of any court, governmental authority or administrative or other
agency having jurisdiction over it or (ii) violate, breach or constitute a default under (with or without notice or lapse of time) MAP’s obligations under any other agreement, contract, commitment or instrument by which it or any of its
assets are bound. 
 8.      INDEMNIFICATION. 
 8.1      XEMPLAR Indemnification. XEMPLAR shall defend, indemnify and hold harmless MAP, its Affiliates, directors,
employees and consultants from and against any and all losses (including reasonable attorney’s fees) arising from or related to: 
 (a)      any material breach of this Agreement by XEMPLAR, including but not limited to, XEMPLAR’s representations and warranties herein; or 
  

 16 
 [ *
] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 (b)      any negligence, recklessness or intentional misconduct by
XEMPLAR in performing its obligations under this Agreement or with respect to the manufacture, storage, handling or delivery of the Product. 
 8.2      MAP Indemnification. MAP shall defend, indemnify and hold harmless XEMPLAR, its Affiliates, directors, employees and consultants from and against any and all losses (including reasonable
attorney’s fees) arising from or related to: 
 (a)      any material breach of this Agreement by
MAP, including but not limited to, MAP’s representations and warranties herein; or 
 (b)      any
negligence, recklessness or intentional misconduct by MAP in performing its obligations under this Agreement or with respect to the manufacture, storage, handling or delivery of the Product. 
 8.3      Insurance. XEMPLAR shall purchase and maintain in force during the term of this Agreement and for three
(3) years after the termination or expiration of this Agreement and at its expense: 
 (a)      premises liability insurance and all-risk property insurance including machinery coverage, written at replacement cost value and with replacement cost endorsement; 
 (b)      Commercial General Liability insurance with per-occurrence and general aggregate limits of not less than
[ * ]; (ii) Products and Completed Operations Liability Insurance with per-occurrence and general aggregate limits of not less than [ * ]; Workers’ Compensation and Employer’s Liability Insurance with
statutory limits for Workers’ Compensation and Employer’s Liability insurance limits of not less than [ * ]; (iv) Professional Services Errors & Omissions Liability Insurance with per claim and aggregate
limits of not less than [ * ] covering sums that XEMPLAR becomes legally obligated to pay as damages resulting from claims made by MAP for errors or omissions committed in the conduct of the services outlined in this Agreement. In
lieu of insurance, Xemplar may self-insure any or a portion of the above required insurance. XEMPLAR shall obtain a waiver from any insurance carrier with whom XEMPLAR carries Workers’ Compensation insurance releasing its subrogation rights
against MAP. MAP shall be named as an additional insured under the Commercial General Liability and Products and Completed Operations Liability insurance policies as respects the manufacturing services outlined in this Agreement. XEMPLAR shall
furnish certificates of insurance for all of the above noted policies and required additional insured status to MAP as soon as practicable after the Effective Date of the Agreement and upon renewal of any such policies. Each insurance policy that is
required under this Section shall be obtained from an insurance carrier with an A.M. Best rating of at least A–VII. 
  

 17 
 [ *
] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 9.      TERM AND
TERMINATION. 
 9.1      Term. The term of this Agreement commences as of the
Effective Date and, unless sooner terminated as specifically provided in this Agreement, shall continue in effect until January 31, 2012 (the “Initial Term”); provided, however, that this Agreement shall automatically continue
in effect from year to year after January 31, 2012 (each a “Renewal Term”) unless either Party shall give written notice to the other, at least one (1) year prior to the end of the Initial Term or one (1) year prior
to the end of any renewal term, that it does not wish this Agreement to be renewed past the expiration of such term. 
 9.2      Termination by MAP. Anything herein to the contrary notwithstanding, this Agreement may be terminated by MAP at any time upon 60 days’ written notice upon MAP’s reasonable
determination that XEMPLAR does not have the capability to manufacture Product in accordance with the warranty set forth in Section 3.7 or in quantities sufficient to meet MAP’s requirements as set forth in Section 3 of this
Agreement. 
 9.3      Termination for Default. If either Party believes the other is in material
default or breach of any of its obligations under this Agreement, it may give notice of such default to the other Party, which Party has one-hundred twenty (120) days in which to remedy such default, or sixty (60) days in the case of
default in payment. Such one-hundred twenty (120) day period will be extended in the case of a default not capable of being remedied in such one-hundred twenty (120) day period so long as the defaulting Party uses diligent efforts to
remedy such default and is pursuing a course of action that, if successful, will affect such a remedy within a reasonable period thereafter. If such default is not remedied in the time period set forth above, this Agreement shall automatically
terminate. 
 9.4      Surviving Obligations. Upon the termination of this Agreement for any reason,
XEMPLAR shall complete any Firm Orders for Product that were made by MAP and accepted by XEMPLAR prior to such termination date, and MAP shall pay XEMPLAR for any Product produced in accordance with such orders at the then applicable price in effect
on the effective date of termination hereunder. In addition, provided that a Firm Order is delivered by MAP no later than thirty (30) days before the effective date of any termination, XEMPLAR shall supply to MAP the quantity of Product as
specified by MAP in said Firm Order for up to twelve (12) months after XEMPLAR’s receipt of such order from MAP. The obligations of the Parties under Section 2.2(d) (MAP Loan), Section 3.7 (Warranty), Section 4.4 (Product
Recall), Section 5.2 (Retention of Samples), Section 5.6 (Manufacturing Records), Article 6 (Confidentiality; Proprietary Rights), Article 8 (Indemnification), this Article 9 (Term and Termination) and Article 10 (Miscellaneous) shall
survive the termination or expiration of this Agreement. Termination by a Party shall not be an exclusive remedy and all other remedies will be available to the terminating Party, in equity and at law. 
 10.      MISCELLANEOUS. 
 10.1      No Agency. Neither Party is, nor shall be deemed to be, an employee, agent, co-venturer or legal
representative of the other Party for any purpose. Neither Party will 

  

 18 
 [ *
] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
be entitled to enter into any contracts in the name of, or on behalf of the other Party, nor will either Party be entitled to pledge the credit of the other
Party in any way or hold itself out as having the authority to do so. 
 10.2      Assignment. Except as
otherwise provided herein, neither this Agreement nor any interest hereunder is assignable by any Party without the prior written consent of the other (which consent will not be unreasonably withheld following the conclusion of a party’s
obligations under this Agreement); provided, however, that either Party may assign this Agreement and any interest hereunder in whole or in part, to any Affiliate or to any successor by merger or sale of substantially all of its business unit to
which this Agreement relates in a manner such that the assignor (if it continues as a separate entity) will remain liable and responsible for the performance and observance of all its duties and obligations hereunder. This Agreement is binding upon
the successors and permitted assignees of the Parties and the name of a Party appearing herein is deemed to include the names of such Party’s successor’s and permitted assigns to the extent necessary to carry out the intent of this
Agreement. Any assignment not in accordance with this Section is void. 
 10.3      Further Actions.
Each Party agrees to execute, acknowledge and deliver such further instruments, and to do all such other acts, as may be necessary or appropriate in order to carry out the purposes and intent of this Agreement. 
 10.4      Force Majeure. Neither Party is liable to the other Party for loss or damages or, except as otherwise set
forth in Article 9, has any right to terminate this Agreement for any default or delay attributable to any event beyond its reasonable control and without its fault or negligence (a “Force Majeure Event”), including but not limited to acts
of God, acts of government (including injunctions), fire, flood, earthquake, strike, labor dispute, and the like. The Party affected will give prompt notice of any such cause to the other Party. The Party giving such notice shall thereupon be
excused from such of its obligations hereunder as it is thereby disabled from performing for so long as it is so disabled and for [ * ] and the Party receiving notice shall be similarly excused from its respective obligations which
it is thereby disabled from performing; provided, however, that such affected Party commences and continues to take reasonable and diligent actions to cure such cause. If the Parties are unable to resolve a default or delay in performance of a
Party’s duties under this Agreement due to an event under this Section within [ * ], then the Party will exert commercially reasonable efforts to find a third party to supply to the other Party the product or services, which
are the subject of the default, at commercially reasonable prices/costs. Notwithstanding the foregoing, nothing in this Section will excuse or suspend the obligation to make any payment due hereunder in the manner and at the time provided.

 10.5      Notices. All notices and other communications hereunder shall be in writing and is deemed
given if delivered personally or by facsimile transmission (receipt verified), mailed by registered or certified mail (return receipt requested), postage prepaid, or sent by nationally recognized express courier service, to the Parties at the
following addresses (or at such other address for a Party as shall be specified by like notice; provided, that notices of a change of address is effective only upon receipt thereof): 
  

 19 
 [ *
] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

					
	If to MAP, addressed to:	 	 MAP Pharmaceuticals, Inc.
 2400 Bayshore
Parkway, 2nd Floor
 Mountain View, CA 94043
 Attention: Chief
Executive Officer
	  	
			
	If to XEMPLAR, addressed to:	 	 XEMPLAR Pharmaceuticals, LLC
 200 Riggenback
Road
 Fall River, MA 02720
 Attention: President
	  	

 10.6      Amendment. No amendment, modification or supplement
of any provision of this Agreement shall be valid or effective unless made in writing and signed by a duly authorized officer of each Party. 
 10.7      Waiver. No provision of this Agreement is waived by any act, omission or knowledge of a Party or its agents or employees except by an instrument in writing expressly waiving such provision and
signed by a duly authorized officer of the waiving Party. 
 10.8      Counterparts. This Agreement may
be executed simultaneously in two counterparts, either one of which need not contain the signature of more than one Party but both such counterparts taken together will constitute one and the same agreement. 
 10.9      Descriptive Headings. The descriptive headings of this Agreement are for convenience only, and have no
force or effect in construing or interpreting any of the provisions of this Agreement. 
 10.10      Governing Law. This Agreement is governed by and interpreted in accordance with the substantive laws of the State of California, USA without regard to its or any other jurisdiction’s
choice of law rules. 
 10.11      Severability. Whenever possible, each provision of this Agreement is
interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Agreement is held to be prohibited by or invalid under applicable law, such provision shall be ineffective only to the extent of such
prohibition or invalidity, without invalidating the remainder of this Agreement. In the event of such invalidity, the Parties will seek to agree on an alternative enforceable provision that preserves the original purpose of this Agreement.

 10.12      Entire Agreement of the Parties. This Agreement and the Exhibits attached hereto,
constitute and contain the complete, final and exclusive understanding and agreement of the Parties hereto, and cancel and supersede any and all prior negotiations, correspondence, understandings and agreements, whether oral or written, [including
the Non-Disclosure Agreement,] between the Parties respecting the subject matter hereof, and neither Party is liable or bound to any other Party in any manner by any representations, warranties, covenants, or agreements except as specifically set
forth herein or therein. Nothing in this Agreement, express or implied, is intended to confer upon any Party, other than the Parties 

  

 20 
 [ *
] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
hereto and their respective successors and assigns, any rights, remedies, obligations, or liabilities under or by reason of this Agreement, except as
expressly provided herein. 
 [Signature Page Follows] 
  

 21 
 [ *
] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 IN WITNESS WHEREOF, the Parties hereto
have as of the Effective Date duly executed this Agreement. 
  

									
	MAP PHARMACEUTICALS, INC.	 		 	XEMPLAR PHARMACEUTICALS, LLC
					
	By:	 	 /s/ Timothy S. Nelson
	 		 	By:	 	 /s/ Charles R. Eck

					
	Name:	 	 Timothy S. Nelson
	 		 	Name:	 	 Charles R. Eck

					
	Title:	 	 President and CEO
	 		 	Title:	 	 President

  

 22 
 [ *
] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 EXHIBIT A 
 PRODUCT SPECIFICATIONS 
 [ * ] 
  

 [ * ] Certain information in this document has been omitted and filed separately with the Securities and Exchange
Commission. Confidential treatment has been requested with respect to the omitted portions. 

 EXHIBIT B 
 FACILITY CONVERSION TIMELINE 
 [ * ] 
  

											
	  Area	  	[ * ]    	  	[ * ]    	  	[ * ]    	  	[ * ]    	  	Total
	  Area A	  	      [ * ]    	  	      [ * ]    	  	      [ * ]    	  	      [ * ]    	  	      [ * ]    
	  [ * ]	  	      [ * ]    	  	  	  	  	  	  	  	      [ * ]    
	  Area B	  	  	  	      [ * ]    	  	      [ * ]    	  	      [ * ]    	  	      [ * ]    
	  Area C	  	  	  	  	  	      [ * ]    	  	      [ * ]    	  	      [ * ]    
	  Area D	  	  	  	  	  	  	  	      [ * ]    	  	      [ * ]    
	  Total	  	      [ * ]    	  	      [ * ]    	  	      [ * ]    	  	      [ * ]    	  	      [ * ]    

  
 Area A = [ * ]  

Area B = [ * ]  
 Area C = [ * ] 

 Area D = [ * ]  
  

 2 
 [ *
] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 EXHIBIT C 
 LOAN ADVANCE SCHEDULE* 
 [ * ] 
  

 3 
 [ *
] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 EXHIBIT D 
 FACILITY STAFFING PLAN 
 [ * ] 
  

 4 
 [ *
] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 EXHIBIT E 
 SECOND QUARTER 2006 FORECAST 
 [ * ] 
  

 5 
 [ *
] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 EXHIBIT F 
 CERTAIN TESTING REQUIREMENTS 
  

 6 
 [ *
] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 EXHIBIT G 
 QUALITY INSPECTION POINTS 
 1.      [ * ]  
 2.      [ * ]  
 3.      [ * ]  
  

 7 
 [ *
] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 EXHIBIT G 
 DEDICATED EQUIPMENT 
  

 8 
 [ *
] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00125-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00125-of-00352.parquet"}]]